Minerva Neurosciences Inc Aktienkurs
Ist Minerva Neurosciences Inc eine Topscorer-Aktie nach der Dividenden-, High-Growth-Investing- oder Levermann-Strategie?
Als kostenloser aktien.guide Basis-Nutzer kannst Du die Scores zu allen 9.086 weltweiten Aktien einsehen.
aktien.guide Premium
aktien.guide Unlimited
Kennzahlen
📘 Marktkapitalisierung
📈 Was ist das?
Die Marktkapitalisierung zeigt, wie viel ein Unternehmen laut Börse aktuell wert ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie hilft Unternehmen in Größenklassen (Large, Mid, Small Cap) einzuordnen und gibt Hinweise auf Marktmacht und Stabilität.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Große Unternehmen gelten als stabiler, zahlen oft Dividenden, wachsen aber langsamer.
- Kleine Firmen können stärker wachsen, sind aber schwankungsanfälliger.
- Die Marktkapitalisierung ist ein guter Indikator für Unternehmensgröße, aber kein Maß für Unter- oder Überbewertung.
📘 Enterprise Value (Unternehmenswert)
📈 Was ist das?
Der Enterprise Value (EV) zeigt, was ein Unternehmen tatsächlich kostet, wenn man es komplett übernehmen würde – inklusive Schulden und abzüglich Cash.
🧮 Wie wird es berechnet?
(= Marktkapitalisierung + Nettoverschuldung)
🏛️ Wofür ist es wichtig?
Der EV ist eine realistischere Bewertungsbasis als die Marktkapitalisierung, da er die Kapitalstruktur berücksichtigt. Er ist Grundlage für Kennzahlen wie EV/FCF oder EV/Sales.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Der Enterprise Value zeigt, was ein Unternehmen tatsächlich wert ist – unabhängig davon, wie es finanziert ist.
- Er ist besonders wichtig für professionelle Investoren, da er eine objektivere Grundlage für Bewertungsvergleiche bietet als die Marktkapitalisierung allein.
- Ein Unternehmen mit hoher Verschuldung erscheint im EV teurer, eines mit viel Cash günstiger – auch wenn sie an der Börse gleich viel wert sind.
📘 Nettoverschuldung
📈 Was ist das?
Die Nettoverschuldung zeigt, wie viele Schulden nach Abzug des verfügbaren Cashs tatsächlich verbleiben.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie zeigt, wie stark ein Unternehmen von Fremdkapital abhängig ist – und wie gut es in der Lage ist, seine Schulden kurzfristig zu bedienen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine niedrige oder negative Nettoverschuldung bedeutet hohe finanzielle Stabilität.
- Unternehmen mit viel Cash und geringer Verschuldung sind besser gerüstet für Krisen.
- Eine hohe Nettoverschuldung erhöht das Risiko – besonders bei steigenden Zinsen oder konjunkturellen Schwächen.
📘 Cash
📈 Was ist das?
Der Cashbestand zeigt, wie viele liquide Mittel einem Unternehmen sofort zur Verfügung stehen.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Er gibt Auskunft über die finanzielle Flexibilität: Ein hoher Cashbestand ermöglicht Investitionen, Rückkäufe oder Krisenresistenz.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Cashbestand zeigt finanzielle Stärke und Handlungsspielraum.
- Cash kann für Investitionen, Schuldentilgung oder Aktienrückkäufe genutzt werden.
- Allerdings: Zu viel ungenutztes Kapital kann auch auf mangelnde Investitionsideen hinweisen.
📘 Anzahl ausstehender Aktien
📈 Was ist das?
Die Anzahl ausstehender Aktien gibt an, wie viele Aktien eines Unternehmens aktuell im Umlauf sind und von Investoren gehalten werden.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie ist die Grundlage für viele Kennzahlen wie Gewinn je Aktie (EPS), Marktkapitalisierung oder KGV.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Je weniger Aktien im Umlauf sind, desto höher fällt z. B. der Gewinn je Aktie aus – wichtig für Bewertung und Dividendenrendite.
- Aktienrückkäufe verringern die Anzahl ausstehender Aktien – und steigern den Wert je Aktie.
- Kapitalerhöhungen haben den gegenteiligen Effekt: mehr Aktien → Verwässerung der bestehenden Anteile.
📘 Kurs-Gewinn-Verhältnis (KGV)
📈 Was ist das?
Das KGV zeigt, wie oft der Gewinn pro Aktie im aktuellen Aktienkurs enthalten ist – also wie „teuer“ eine Aktie im Verhältnis zum Gewinn ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das KGV gehört zu den bekanntesten Bewertungskennzahlen. Es hilft Anlegern einzuschätzen, ob eine Aktie im Vergleich zu ihrem Gewinn eher günstig oder teuer erscheint.
🧮 Berechnung
📊 KGV (TTM) = bezogen auf den Gewinn der letzten 12 Monate (Trailing Twelve Months):🎯 Was bedeutet das für Anleger?
- Ein niedriges KGV kann auf eine günstige Bewertung hindeuten – oder auf Probleme im Geschäftsmodell.
- Ein hohes KGV kann Wachstumserwartungen widerspiegeln – oder eine überbewertete Aktie.
📘 Kurs-Umsatz-Verhältnis (KUV)
📈 Was ist das?
Das KUV zeigt, wie viel Anleger für 1 € Umsatz eines Unternehmens zahlen – unabhängig vom Gewinn.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das KUV ist besonders bei wachstumsstarken oder noch nicht profitablen Unternehmen hilfreich. Es zeigt, wie hoch der Umsatz an der Börse bewertet wird.
🎯 Was bedeutet das für Anleger?
- Ein niedriges KUV kann auf Unterbewertung hindeuten – oder auf schwache Margen.
- Ein hohes KUV kann hohe Erwartungen widerspiegeln – oder übermäßigen Optimismus.
- Besonders sinnvoll bei Wachstumsunternehmen, bei denen der Gewinn oder Free Cashflow (noch) keine Aussagekraft hat.
📘 Unternehmenswert zu Umsatz (EV/Sales)
📈 Was ist das?
EV/Sales zeigt, wie viel Anleger für 1 € Umsatz eines Unternehmens zahlen, wenn man auch Schulden und Cash berücksichtigt – es ist eine kapitalstrukturbereinigte Version des KUV.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Diese Kennzahl eignet sich besonders für den Vergleich von Unternehmen mit unterschiedlicher Verschuldung – sie zeigt, wie teuer ein Unternehmen tatsächlich im Verhältnis zum Umsatz ist.
🎯 Was bedeutet das für Anleger?
- EV/Sales ist neutral gegenüber der Kapitalstruktur und eignet sich gut für Unternehmensvergleiche.
- Ein niedriges Verhältnis kann auf eine günstig bewertete Aktie hindeuten – ein hohes Verhältnis auf hohe Erwartungen oder Überbewertung.
- Besonders nützlich bei wachstumsstarken, noch nicht profitablen Firmen.
📘 Unternehmenswert zu Free Cashflow (EV/FCF) | ex SBC
📈 Was ist das?
EV/FCF setzt den Unternehmenswert eines Unternehmens ins Verhältnis zu seinem Free Cashflow. Die Kennzahl zeigt damit, mit welchem Vielfachen des aktuellen Free Cashflows ein Unternehmen bewertet wird. EV/FCF ex SBC berücksichtigt zusätzlich aktienbasierte Vergütungen (Stock-Based Compensation, SBC). SBC verursacht zwar keinen direkten Cash-Abfluss, kann bestehende Aktionäre jedoch durch die Ausgabe zusätzlicher Aktien verwässern. Deshalb wird SBC bei dieser Variante vom Free Cashflow abgezogen.
🧮 Wie wird es berechnet?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cashflow (TTM) − SBC)
🏛️ Wofür ist es wichtig?
EV/FCF ermöglicht eine Bewertung auf Basis des Free Cashflows und ergänzt damit gewinnbasierte Bewertungskennzahlen wie das KGV. Die Variante ex SBC berücksichtigt zusätzlich die wirtschaftliche Belastung durch aktienbasierte Vergütungen und ermöglicht dadurch eine konservativere Betrachtung aus Sicht der Aktionäre.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein niedriges EV/FCF bedeutet, dass der Unternehmenswert im Verhältnis zum aktuellen Free Cashflow niedrig ist. Die Ursachen dafür sollten jedoch immer im Unternehmens- und Branchenkontext betrachtet werden.
- Ein hohes EV/FCF bedeutet, dass der Unternehmenswert im Verhältnis zum aktuellen Free Cashflow hoch ist. Das kann beispielsweise auf hohe Wachstumserwartungen oder eine vorübergehend schwache Cash-Generierung zurückzuführen sein.
- Bei positiver SBC und positivem bereinigtem Free Cashflow fällt EV/FCF ex SBC in der Regel höher aus als das klassische EV/FCF.
- Besonders aussagekräftig ist die Kennzahl bei Unternehmen mit relativ stabilen und gut einschätzbaren Cashflows.
- Bei negativem oder sehr niedrigem Free Cashflow ist EV/FCF nur eingeschränkt aussagekräftig und sollte nicht wie ein gewöhnliches Bewertungsmultiple interpretiert werden.
📘 Kurs-Buchwert-Verhältnis (KBV)
📈 Was ist das?
Das KBV zeigt, wie hoch der Marktwert eines Unternehmens im Verhältnis zu seinem bilanziellen Eigenkapital ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das KBV ist besonders bei Substanzwerten (z. B. Banken, Industrie) relevant. Es hilft Anlegern zu erkennen, ob ein Unternehmen unter oder über seinem buchhalterischen Vermögen bewertet ist.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein KBV unter 1 kann auf Unterbewertung oder schwache Rentabilität hindeuten.
- Ein KBV über 1 zeigt, dass der Markt dem Unternehmen Mehrwert über den Buchwert hinaus zuschreibt (z. B. Marken, Patente, Wachstum).
- Das KBV eignet sich besonders gut für Unternehmen mit stabilen, materiellen Vermögenswerten.
📘 Eigenkapitalquote
📈 Was ist das?
Die Eigenkapitalquote zeigt, wie hoch der Anteil des Eigenkapitals an der Bilanzsumme eines Unternehmens ist – also wie stark es sich aus eigenen Mitteln finanziert.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Eine hohe Eigenkapitalquote steht für finanzielle Stabilität, Krisenfestigkeit und gute Bonität. Sie ist besonders relevant bei der Beurteilung der Verschuldung.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe Eigenkapitalquote signalisiert finanzielle Stabilität – besonders in Krisenzeiten.
- Ein niedriger Wert kann auf ein höheres Risiko oder eine aggressive Verschuldung hinweisen.
- Wichtig: Die Eigenkapitalquote sollte immer gemeinsam mit der Eigenkapitalrendite betrachtet werden. Nur so lässt sich beurteilen, ob ein Unternehmen nicht nur solide, sondern auch effizient wirtschaftet.
📘 Eigenkapitalrendite (ROE)
📈 Was ist das?
Die Eigenkapitalrendite zeigt, wie effizient ein Unternehmen mit dem Kapital seiner Aktionäre arbeitet – also wie viel Gewinn es pro Euro Eigenkapital erwirtschaftet.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Eigenkapitalrendite ist eine zentrale Rentabilitätskennzahl. Sie hilft Anlegern zu erkennen, ob das Unternehmen eine attraktive Verzinsung auf das eingesetzte Eigenkapital erwirtschaftet.
🎯 Was bedeutet das für Anleger?
- Eine hohe Eigenkapitalrendite spricht für ein starkes, effizientes Geschäftsmodell.
- Besonders interessant ist sie bei kapitalintensiven Firmen oder solchen mit hoher Eigenkapitalquote.
- Wichtig: Ein sehr hoher ROE kann auch auf hohe Schulden hinweisen – daher sollte sie immer im Kontext mit der Eigenkapitalquote betrachtet werden.
📘 Return on Capital Employed (ROCE)
📈 Was ist das?
ROCE misst die Gesamtrentabilität eines Unternehmens – also wie effizient es das eingesetzte Kapital (Eigen- und Fremdkapital) zur Gewinnerzielung nutzt.
🧮 Wie wird es berechnet?
Das eingesetzte Kapital ist das gesamte betriebsnotwendige Kapital, unabhängig von der Finanzierungsquelle.
🏛️ Wofür ist es wichtig?
ROCE eignet sich besonders gut für den Vergleich unterschiedlich finanzierter Unternehmen. Es zeigt, wie effektiv ein Unternehmen Kapital investiert – unabhängig von der Kapitalstruktur.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher ROCE zeigt, dass ein Unternehmen sein Kapital effizient einsetzt – unabhängig davon, ob es durch Eigen- oder Fremdkapital finanziert ist.
- Je höher der ROCE im Vergleich zu ähnlichen Unternehmen, desto mehr Wert schafft das Unternehmen mit seinem investierten Kapital.
- Besonders wichtig ist der ROCE bei Firmen mit hohen Investitionen – z. B. in Industrie, Energie oder Infrastruktur.
📘 Return on Invested Capital (ROIC)
📈 Was ist das?
ROIC zeigt, wie effizient ein Unternehmen das Kapital investiert, das langfristig im operativen Geschäft gebunden ist – unabhängig davon, ob es aus Eigen- oder Fremdkapital stammt.
🧮 Wie wird es berechnet?
- NOPAT = „Net Operating Profit After Taxes“
- Investiertes Kapital = operatives Vermögen abzüglich nicht-verzinster Schulden
🏛️ Wofür ist es wichtig?
ROIC ist eine der präzisesten Kennzahlen zur Bewertung der Kapitalrendite – besonders im Vergleich zur Eigenkapitalrendite, weil es Verzerrungen durch Schulden vermeidet. Er zeigt, ob ein Unternehmen Mehrwert für alle Kapitalgeber schafft.
🎯 Was bedeutet das für Anleger?
- Ein hoher ROIC zeigt, wie gut ein Unternehmen mit dem tatsächlich investierten (betriebsnotwendigen) Kapital wirtschaftet.
- Im Unterschied zu ROCE wird nur Kapital betrachtet, das wirklich zur Finanzierung operativer Aktivitäten dient – und verzinst werden muss.
- Besonders hilfreich, um die Kapitalrendite von Unternehmen mit viel „überschüssigem“ Kapital oder zinsfreien Verbindlichkeiten realistisch zu vergleichen.
📘 Verschuldungsgrad (Leverage Ratio)
📈 Was ist das?
Der Verschuldungsgrad zeigt, wie stark ein Unternehmen durch verzinsliche Schulden (z. B. Kredite und Anleihen) im Verhältnis zum Eigenkapital finanziert ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Kennzahl hilft, das finanzielle Risiko und die Abhängigkeit von Fremdkapital zu beurteilen. Ein hoher Verschuldungsgrad kann die Eigenkapitalrendite steigern – birgt aber auch erhöhte Risiken bei Zinsanstiegen oder Liquiditätsengpässen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein niedriger Verschuldungsgrad steht für finanzielle Stabilität und Unabhängigkeit.
- Ein hoher Wert kann auf erhöhte Risiken hinweisen – insbesondere bei schwankenden Zinsen oder konjunkturellen Schwächen.
- Wichtig: Immer im Kontext zur Branche und Kapitalintensität bewerten.
📘 SBC | in % Umsatz
📈 Was ist das?
SBC (Stock-Based Compensation) bezeichnet die aktienbasierte Vergütung, die ein Unternehmen seinen Mitarbeitern und Führungskräften gewährt. Der Prozentanteil zeigt, wie hoch die SBC im Verhältnis zum Umsatz ist.
🧮 Wie wird es berechnet?
SBC in % Umsatz = (SBC ÷ Umsatz) × 100
🏛️ Wofür ist es wichtig?
Aktienbasierte Vergütung ist für Aktionäre ein realer Kostenfaktor. Sie erhöht die Aktienanzahl und verwässert damit die bestehenden Anteile. Der Anteil am Umsatz zeigt, wie stark ein Unternehmen auf dieses Mittel setzt und wie viel der Wertschöpfung an Mitarbeiter statt an Aktionäre fließt.
🎯 Was bedeutet das für Anleger?
- Ein niedriger Wert ist grundsätzlich positiv: Die aktienbasierte Vergütung fällt im Verhältnis zum Umsatz gering aus.
- Ein hoher Wert kann dagegen auf eine stärkere Abhängigkeit von aktienbasierter Vergütung und ein höheres potenzielles Verwässerungsrisiko hindeuten. Entscheidend ist dabei auch, ob das Unternehmen die Verwässerung durch Aktienrückkäufe ausgleicht.
📘 SBC in % FCF
📈 Was ist das?
SBC (Stock-Based Compensation) bezeichnet die aktienbasierte Vergütung, die ein Unternehmen seinen Mitarbeitern und Führungskräften gewährt. Der Prozentanteil zeigt, wie hoch die SBC im Verhältnis zum Free Cashflow (FCF) ist.
🧮 Wie wird es berechnet?
SBC in % FCF = (SBC ÷ Free Cashflow) × 100
🏛️ Wofür ist es wichtig?
Aktienbasierte Vergütung ist für Aktionäre ein realer Kostenfaktor. Sie erhöht die Aktienanzahl und verwässert damit die bestehenden Anteile. Der Anteil am freien Cashflow zeigt, wie groß die SBC im Verhältnis zur vom Unternehmen erwirtschafteten Cash-Generierung ist. Da SBC nicht zahlungswirksam ist, wird sie bei der Berechnung des FCF typischerweise nicht als Cash-Abfluss berücksichtigt.
🎯 Was bedeutet das für Anleger?
- Ein niedriger Wert ist hier meist günstig. Die aktienbasierte Vergütung fällt im Verhältnis zur Cash-Erzeugung gering aus.
- Ein hoher Wert bedeutet, dass ein großer Teil des ausgewiesenen freien Cashflows durch nicht zahlungswirksame SBC gestützt wird.
- Je höher der Wert, desto stärker kann die SBC die tatsächliche wirtschaftliche Belastung für Aktionäre widerspiegeln.
📘 SBC-Wachstum 1J
📈 Was ist das?
Das SBC-Wachstum 1J zeigt, wie stark sich die aktienbasierte Vergütung (Stock-Based Compensation) eines Unternehmens im Vergleich zum Vorjahr verändert hat.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das SBC-Wachstum zeigt, ob die aktienbasierte Vergütung für Aktionäre zunehmend oder abnehmend relevant wird. Steigt die SBC deutlich, kann dadurch langfristig auch die Verwässerung der Aktionäre zunehmen. Gleichzeitig handelt es sich um einen nicht zahlungswirksamen Aufwand, der in der Gewinn- und Verlustrechnung das Ergebnis mindert, in der Kapitalflussrechnung jedoch wieder hinzugerechnet wird.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher positiver Wert ist meistens negativ, denn steigende SBC kann die Belastung für Aktionäre erhöhen, insbesondere durch mögliche Verwässerung.
- Entscheidend ist, ob die Entwicklung der SBC langfristig nachhaltig bleibt. Ein gewisses Maß an SBC ist bei vielen Wachstums- und Technologieunternehmen üblich.
📘 Aktienanzahl-Wachstum 1J
📈 Was ist das?
Das Wachstum der Aktienanzahl zeigt, wie stark sich die Zahl der ausstehenden Aktien innerhalb eines Jahres verändert hat.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Aktienanzahl bestimmt, auf wie viele Anteile sich Gewinn und Vermögen des Unternehmens verteilen. Sinkt die Anzahl der Aktien, steigt der relative Anteil bestehender Aktionäre. Steigt sie, werden bestehende Aktionäre verwässert. Die Kennzahl macht damit Verwässerung und Aktienrückkäufe direkt sichtbar.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein negativer Wert ist meist positiv, da die Zahl der ausstehenden Aktien zurückgeht.
- Ein positiver Wert deutet auf eine Verwässerung bestehender Aktionäre hin.
- Ein sinkender Wert ist nicht automatisch positiv: Entscheidend ist auch, zu welchem Preis und wie die Rückkäufe finanziert werden.
📘 Shareholder Yield
📈 Was ist das?
Der Shareholder Yield zeigt, wie viel ein Unternehmen im Verhältnis zu seiner Marktkapitalisierung über Dividenden und Aktienrückkäufe an seine Aktionäre zurückgibt. Damit geht die Kennzahl über die klassische Dividendenrendite hinaus.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Dividendenrendite allein zeigt nur einen Teil davon, wie ein Unternehmen Kapital an seine Aktionäre zurückgibt. Sinkt die Aktienanzahl durch Rückkäufe, steigt der Anteil jedes bestehenden Aktionärs am Unternehmen. Steigt sie, etwa durch Aktienvergütung oder Kapitalerhöhungen, wird dieser Anteil verwässert. Der Shareholder Yield fasst beides in einer Kennzahl zusammen.
🎯 Was bedeutet das für Anleger?
- Ein höherer Wert bedeutet mehr Kapitalrückgabe an die Aktionäre.
- Ein negativer Wert bedeutet, dass mehr neue Aktien ausgegeben wurden, als Dividende und Rückkäufe ausgleichen.
- Rückkäufe schaffen nur dann Wert, wenn die Aktien zu attraktiven Preisen zurückgekauft werden.
- Entscheidend ist auch, ob die Kapitalrückgaben nachhaltig finanziert werden.
📘 Umsatz
📈 Was ist das?
Der Umsatz zeigt, wie viel ein Unternehmen insgesamt mit seinen Produkten und Dienstleistungen verdient – also den Bruttoerlös vor Abzug von Kosten.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Der Umsatz ist eine der zentralen Kennzahlen zur Einschätzung der Unternehmensgröße, Marktstellung und Wachstumskraft.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein wachsender Umsatz zeigt eine steigende Nachfrage und kann ein guter Frühindikator für Gewinnsteigerungen sein.
- Vergleiche von aktuellem und erwartetem Umsatz geben Hinweise auf das Marktumfeld und Analystenerwartungen.
- Wichtig: Starker Umsatz allein genügt nicht – auch Margen und Profitabilität zählen.
📘 EBITDA
📈 Was ist das?
EBITDA steht für „Earnings Before Interest, Taxes, Depreciation and Amortization“ – also Gewinn vor Zinsen, Steuern und Abschreibungen. Es zeigt das operative Ergebnis eines Unternehmens, bereinigt um bilanztechnische und finanzierungsbedingte Effekte.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
EBITDA ist eine verbreitete Kennzahl zur Beurteilung der operativen Leistungsfähigkeit – insbesondere bei kapitalintensiven Unternehmen oder im internationalen Vergleich.
🎯 Was bedeutet das für Anleger?
- Ein hohes oder wachsendes EBITDA spricht für starke operative Erträge – unabhängig von Bilanzierung oder Steuerlast.
- EBITDA ist besonders nützlich, um Unternehmen branchenübergreifend zu vergleichen.
- Wichtig: EBITDA ist keine offizielle Gewinnkennzahl – Abschreibungen und Finanzierungskosten werden ausgeklammert.
📘 EBIT
📈 Was ist das?
EBIT steht für „Earnings Before Interest and Taxes“ – also Gewinn vor Zinsen und Steuern. Es zeigt das operative Ergebnis eines Unternehmens nach Abschreibungen, aber vor Finanzierungs- und Steueraufwand.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
EBIT ist eine zentrale Kennzahl zur Beurteilung der Profitabilität aus dem Kerngeschäft – unabhängig von Kapitalstruktur oder Steuersystem.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hohes EBIT deutet auf ein profitables Kerngeschäft hin – vor Zinslasten oder steuerlichen Effekten.
- Es erlaubt objektivere Vergleiche zwischen Unternehmen mit unterschiedlicher Finanzierung.
- Im Vergleich mit EBITDA zeigt EBIT bereits den Einfluss von Abschreibungen auf das operative Ergebnis.
📘 Nettogewinn
📈 Was ist das?
Der Nettogewinn ist der verbleibende Jahresüberschuss (oder -fehlbetrag) eines Unternehmens – nach Abzug aller Kosten, Steuern, Zinsen und Abschreibungen
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Der Nettogewinn ist die zentrale Erfolgskennzahl – er zeigt, wie profitabel ein Unternehmen nach allen Kosten tatsächlich arbeitet.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein steigender Nettogewinn zeigt, dass das Unternehmen effizient wirtschaftet – trotz aller Kosten.
- Die Entwicklung des Gewinns beeinflusst z. B. direkt das KGV und weitere Kennzahlen.
- Im Zeitverlauf lässt sich ablesen, wie stabil und profitabel ein Geschäftsmodell wirklich ist.
📘 Free Cashflow (FCF) | ex SBC
📈 Was ist das?
Der Free Cashflow gibt an, wie viel Bargeld tatsächlich übrig bleibt, nachdem ein Unternehmen seine Betriebsausgaben und Investitionsausgaben gedeckt hat. Der FCF ex SBC zieht zusätzlich die aktienbasierte Vergütung ab, um den Cashflow um den Effekt der nicht zahlungswirksamen SBC zu bereinigen.
🧮 Wie wird es berechnet?
Free Cashflow ex SBC = Operativer Cashflow − SBC − Investitionen in Sachanlagen (CAPEX)
🏛️ Wofür ist es wichtig?
Der FCF spiegelt die tatsächliche Finanzkraft eines Unternehmens wider – unabhängig von den bilanziellen Gewinnen. Er zeigt, wie viel Spielraum ein Unternehmen für Dividenden, Aktienrückkäufe oder den Schuldenabbau hat. Der FCF ex SBC zieht zusätzlich die aktienbasierte Vergütung ab und zeigt, wie hoch die Cash-Generierung nach Abzug der SBC ausfällt.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Free Cashflow bedeutet, dass ein Unternehmen echte Finanzkraft besitzt – unabhängig vom bilanzierten Gewinn.
- Er ist oft die solideste Grundlage für nachhaltige Dividenden und Aktienrückkäufe.
- Sinkender FCF kann ein Warnsignal sein – auch wenn der Gewinn stabil aussieht.
📘 Umsatzwachstum
📈 Was ist das?
Das Umsatzwachstum zeigt, wie stark sich die Erlöse eines Unternehmens im Vergleich zum Vorjahr verändert haben – tatsächlich (TTM) und auf Prognosebasis (erwartet).
🧮 Wie wird es berechnet?
Erwartet = (Umsatz erwartet ÷ Umsatz Vorjahr − 1) × 100
Erwartetes Wachstum basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Ein wachsender Umsatz ist ein zentrales Signal für steigende Nachfrage, Geschäftsausweitung und Marktanteilsgewinne – besonders bei Wachstumsunternehmen.
🎯 Was bedeutet das für Anleger?
- Wachstum ist der Motor langfristiger Wertsteigerung – besonders bei Technologie- und Wachstumsaktien.
- Wichtig ist nicht nur das aktuelle Wachstum, sondern auch dessen Nachhaltigkeit.
- Prognosen zeigen, ob Analysten weiteres Potenzial erwarten – oder eine Verlangsamung.
📘 EBITDA-Wachstum
📈 Was ist das?
Das EBITDA-Wachstum zeigt, wie stark das operative Ergebnis eines Unternehmens vor Zinsen, Steuern und Abschreibungen im Vergleich zum Vorjahr gestiegen oder gesunken ist.
🧮 Wie wird es berechnet?
Erwartet = (erwartetes EBITDA ÷ EBITDA Vorjahr − 1) × 100
Erwartetes Wachstum basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Ein steigendes EBITDA ist ein Zeichen für verbesserte operative Ertragskraft – unabhängig von Finanzierungsstruktur oder Abschreibungen.
🎯 Was bedeutet das für Anleger?
- Starkes EBITDA-Wachstum signalisiert operative Effizienz und Skalierung – besonders relevant in Wachstumsphasen.
- EBITDA-Wachstum ist ein Frühindikator für Margen- und Gewinnentwicklung – sollte aber stets im Zusammenhang mit Umsatz und EBIT betrachtet werden.
📘 EBIT Wachstum
📈 Was ist das?
Das EBIT-Wachstum zeigt, wie stark das operative Ergebnis eines Unternehmens (nach Abschreibungen, aber vor Zinsen und Steuern) im Vergleich zum Vorjahr gewachsen ist.
🧮 Wie wird es berechnet?
Erwartet = (erwartetes EBIT ÷ EBIT Vorjahr − 1) × 100
Erwartetes Wachstum basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Das EBIT-Wachstum ist ein direkter Indikator für die wirtschaftliche Entwicklung des operativen Geschäfts – unter Berücksichtigung der Kapitalintensität (Abschreibungen).
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Steigendes EBIT signalisiert wachsende operative Rentabilität – auch unter Berücksichtigung von Abschreibungen.
- Das EBIT-Wachstum ist ein wichtiges Maß zur Beurteilung von Geschäftsmodellen mit hohen Investitionskosten.
- Im Zusammenspiel mit Umsatz- und EBITDA-Wachstum ergibt sich ein umfassendes Bild zur operativen Entwicklung.
📘 Nettogewinn-Wachstum
📈 Was ist das?
Das Nettogewinn-Wachstum zeigt, wie stark der Jahresüberschuss eines Unternehmens gegenüber dem Vorjahr gestiegen oder gesunken ist – sowohl tatsächlich (TTM) als auch auf Basis von Prognosen (erwartet).
🧮 Wie wird es berechnet?
Erwartet = (erwarteter Nettogewinn ÷ Nettogewinn Vorjahr − 1) × 100
Der erwartete Wert basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Der Gewinn ist die entscheidende Ergebnisgröße für ein Unternehmen. Ein wachsender Nettogewinn deutet auf steigende Effizienz, stabile Kostenkontrolle und nachhaltige Ertragskraft hin.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Wachsender Nettogewinn stärkt die Bewertung, Dividendenfähigkeit und Kursfantasie.
- Stagnierender oder rückläufiger Gewinn trotz Umsatzwachstum kann auf Margendruck hinweisen.
📘 Free Cashflow-Wachstum
📈 Was ist das?
Das Free-Cashflow-Wachstum zeigt, wie sich der freie Mittelzufluss eines Unternehmens im Vergleich zum Vorjahr verändert hat – also der Betrag, der nach allen operativen Ausgaben und Investitionen übrig bleibt.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Free Cashflow ist der echte, verfügbare Geldzufluss. Wachstum in diesem Bereich ist ein Zeichen für finanzielle Stärke und steigende Flexibilität bei Dividenden, Rückkäufen oder Investitionen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Sinkender Free Cashflow kann auf steigende Investitionen, höhere Kosten oder stagnierende operative Erträge hindeuten.
- Besonders bei Dividendenwerten ist das FCF-Wachstum wichtig – denn Dividenden werden letztlich aus dem verfügbaren Cash gezahlt.
- Ein negativer Trend sollte genauer analysiert werden – er ist nicht zwangsläufig schlecht, aber potenziell ein Warnsignal.
📘 Bruttomarge
📈 Was ist das?
Die Bruttomarge zeigt, wie viel vom Umsatz nach Abzug der direkten Herstellungskosten (Material, Produktion) als Bruttogewinn übrig bleibt – also der „Rohgewinn“ eines Unternehmens.
🧮 Wie wird es berechnet?
Auch: Bruttomarge = Bruttogewinn ÷ Umsatz × 100
🏛️ Wofür ist es wichtig?
Die Bruttomarge gibt Aufschluss über die Profitabilität eines Produkts oder Geschäftsmodells vor Fixkosten, Steuern und Zinsen. Sie zeigt, wie effizient ein Unternehmen produzieren oder einkaufen kann.
🎯 Was bedeutet das für Anleger?
- Eine hohe Bruttomarge deutet auf starke Preissetzungsmacht und effiziente Herstellung hin.
- Sinkende Bruttomargen können auf Kostensteigerungen oder Preisdruck hindeuten.
- Besonders im Vergleich zu Wettbewerbern liefert die Bruttomarge wertvolle Einblicke in die Geschäftsqualität.
📘 EBITDA-Marge
📈 Was ist das?
Die EBITDA-Marge zeigt, wie viel vom Umsatz als operativer Gewinn vor Zinsen, Steuern und Abschreibungen (EBITDA) übrig bleibt. Sie misst die operative Effizienz – ohne Verzerrungen durch Finanzierung oder Buchwerte.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die EBITDA-Marge hilft zu verstehen, wie viel operativer Gewinn ein Unternehmen aus jedem Euro Umsatz erzielt – unabhängig von Kapitalstruktur oder steuerlichem Umfeld.
🎯 Was bedeutet das für Anleger?
- Eine hohe EBITDA-Marge zeigt starke operative Ertragskraft – unabhängig von Bilanzierungseffekten.
- Die Marge ermöglicht gute Vergleiche zwischen Unternehmen und Branchen.
- Ein stabiler oder wachsender Wert kann auf effiziente Kostenkontrolle und Skalierbarkeit hindeuten.
📘 EBIT-Marge
📈 Was ist das?
Die EBIT-Marge zeigt, wie viel Prozent des Umsatzes als operativer Gewinn nach Abschreibungen, aber vor Zinsen und Steuern übrig bleiben.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die EBIT-Marge misst die operative Ertragskraft eines Unternehmens unter Berücksichtigung der Kapitalintensität (z. B. Maschinen, Anlagen). Sie eignet sich gut zum Vergleich von Geschäftsmodellen mit unterschiedlich hohen Abschreibungen.
🎯 Was bedeutet das für Anleger?
- Eine hohe EBIT-Marge zeigt, dass ein Unternehmen auch nach Abschreibungen effizient arbeitet.
- Sie ist besonders relevant in kapitalintensiven Branchen.
- Langfristig stabile oder steigende Margen sind ein Zeichen wirtschaftlicher Stärke und Preissetzungsmacht.
📘 Nettomarge
📈 Was ist das?
Die Nettomarge zeigt, wie viel vom Umsatz am Ende als „Reingewinn“ übrig bleibt – also nach Abzug aller Kosten, Zinsen, Steuern und Abschreibungen.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Nettomarge gibt an, wie effizient ein Unternehmen über alle Stufen hinweg wirtschaftet. Sie zeigt, wie viel Gewinn tatsächlich je Euro Umsatz übrig bleibt.
🎯 Was bedeutet das für Anleger?
- Eine hohe Nettomarge zeigt, dass ein Unternehmen nicht nur operativ stark ist, sondern auch seine Finanzierung und Steuerbelastung im Griff hat.
- Vergleiche mit Wettbewerbern geben Einblicke in die wirtschaftliche Qualität.
- Sinkende Nettomargen trotz Umsatzwachstum können ein Warnsignal sein – etwa für steigende Kosten oder sinkende Effizienz.
📘 Free-Cashflow-Marge | ex SBC
📈 Was ist das?
Die Free-Cashflow-Marge zeigt, wie viel Free Cashflow ein Unternehmen im Verhältnis zu seinem Umsatz erwirtschaftet. Der Free Cashflow entspricht vereinfacht dem operativen Cashflow abzüglich der Investitionsausgaben. Die Free-Cashflow-Marge ex SBC berücksichtigt zusätzlich aktienbasierte Vergütungen (Stock-Based Compensation, SBC). SBC verursacht zwar keinen direkten Cash-Abfluss, kann bestehende Aktionäre jedoch durch die Ausgabe zusätzlicher Aktien verwässern. Daher wird SBC bei dieser Kennzahl vom Free Cashflow abgezogen.
🧮 Wie wird es berechnet?
Free-Cashflow-Marge ex SBC = (Free Cashflow − SBC) ÷ Umsatz × 100
🏛️ Wofür ist es wichtig?
Die Free-Cashflow-Marge zeigt, wie effizient ein Unternehmen seinen Umsatz in Free Cashflow umwandelt. Ein hoher Free Cashflow kann dem Unternehmen finanziellen Spielraum für Dividenden, Aktienrückkäufe, Schuldentilgung oder weitere Investitionen geben. Die Variante ex SBC berücksichtigt zusätzlich die wirtschaftliche Belastung durch aktienbasierte Vergütungen und ermöglicht dadurch eine konservativere Betrachtung der Cash-Generierung aus Sicht der Aktionäre.
🎯 Was bedeutet das für Anleger?
- Eine hohe Free-Cashflow-Marge zeigt, dass ein Unternehmen einen hohen Anteil seines Umsatzes in Free Cashflow umwandelt.
- Das kann dem Unternehmen mehr finanziellen Spielraum für Dividenden, Aktienrückkäufe, Schuldentilgung oder Investitionen geben.
- Die Free-Cashflow-Marge ex SBC berücksichtigt zusätzlich die mögliche Verwässerung durch aktienbasierte Vergütungen.
- Besonders aussagekräftig ist die Entwicklung über mehrere Jahre. Sinkende Werte können beispielsweise auf höhere Investitionen, Veränderungen im Working Capital oder eine schwächere operative Entwicklung zurückzuführen sein.
📘 Ergebnis je Aktie (EPS)
📈 Was ist das?
Das Ergebnis je Aktie (EPS) zeigt, wie viel Gewinn auf eine einzelne Aktie entfällt – und ist eine der wichtigsten Kennzahlen zur Bewertung von Unternehmen.
🧮 Wie wird es berechnet?
Die verwässerte Aktienanzahl berücksichtigt auch potenzielle neue Aktien, etwa durch Optionen, Wandelanleihen oder andere Umtauschrechte.
🏛️ Wofür ist es wichtig?
EPS bildet die Basis für viele Bewertungskennzahlen wie KGV, PEG oder Payout Ratio. Es macht den Gewinn für Aktionäre vergleichbar – unabhängig von der Unternehmensgröße.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- EPS hilft, die Profitabilität pro Aktie zu erfassen – und ist besonders wichtig im Zeitvergleich oder im Vergleich mit Analystenschätzungen.
- Steigendes EPS kann ein Zeichen für stabiles Wachstum oder Aktienrückkäufe sein.
- Wichtig: Verwende verwässertes EPS für realistische Bewertungen – besonders bei stark aktienbasierten Vergütungssystemen.
📘 Free Cashflow je Aktie (FCF je Aktie)
📈 Was ist das?
Der Free Cashflow je Aktie zeigt, wie viel freier Mittelzufluss einem Unternehmen pro Aktie zur Verfügung steht – nach Investitionen, aber vor Dividenden oder Schuldentilgung.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Der FCF je Aktie zeigt, wie viel liquide Mittel pro Aktie tatsächlich im Unternehmen verbleiben – wichtig für Dividenden, Aktienrückkäufe oder Schuldentilgung. Im Gegensatz zum Gewinn ist er schwerer manipulierbar und daher besonders aussagekräftig.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Free Cashflow je Aktie ist ein Zeichen für hohe finanzielle Flexibilität.
- Er zeigt, wie viel Kapital ein Unternehmen effektiv einsetzen oder ausschütten kann.
- Besonders relevant für dividendenstarke Unternehmen oder solche mit starker Kapitalrendite.
📘 Short Interest
📈 Was ist das?
Short Interest zeigt, wie viele Aktien eines Unternehmens aktuell leerverkauft wurden – also von Investoren geliehen und verkauft, in der Erwartung fallender Kurse.
🧮 Wie wird es berechnet?
Der Wert zeigt den Anteil der Aktien, der aktuell auf fallende Kurse spekuliert wird.
🏛️ Wofür ist es wichtig?
Short Interest dient als Stimmungsindikator: Ein hoher Wert deutet auf Skepsis oder negative Erwartungen gegenüber dem Unternehmen hin – kann aber auch zu einem „Short Squeeze“ führen, wenn der Kurs plötzlich steigt.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein niedriger Short Interest deutet auf Vertrauen in das Unternehmen hin.
- Ein hoher Wert kann ein Warnsignal sein – oder eine Chance, wenn sich die Stimmung dreht.
- Besonders spannend in volatilen Märkten oder vor wichtigen Quartalszahlen.
📘 Employees
📈 Was ist das?
Die Mitarbeiteranzahl zeigt, wie viele Personen ein Unternehmen weltweit beschäftigt – ein Indikator für Größe, Struktur und Geschäftsmodell.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie hilft bei der Einschätzung von Skaleneffekten, Effizienz und Personalkosten. Zusammen mit Umsatz und Gewinn lassen sich Kennzahlen wie Produktivität je Mitarbeiter ableiten.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Viele Mitarbeiter bedeuten große operative Komplexität – aber auch hohes Umsatzpotenzial.
- Produktivität je Mitarbeiter ist ein wichtiger Indikator für Effizienz.
- Besonders spannend bei stark wachsenden Tech- oder Industrieunternehmen.
📘 Umsatz je Mitarbeiter
📈 Was ist das?
Der Umsatz je Mitarbeiter zeigt, wie viel Erlös ein Unternehmen durchschnittlich pro Beschäftigtem erwirtschaftet – eine Kennzahl für Effizienz und Produktivität.
🧮 Wie wird es berechnet?
Die Mitarbeiterzahl stammt in der Regel aus dem letzten verfügbaren Jahresbericht.
🏛️ Wofür ist es wichtig?
Diese Kennzahl hilft, Geschäftsmodelle zu vergleichen – insbesondere zwischen arbeitsintensiven und technologiegetriebenen Unternehmen. Ein hoher Wert deutet auf Automatisierung, Effizienz oder hohen Wertschöpfungsanteil hin.
🎯 Was bedeutet das für Anleger?
- Ein hoher Umsatz je Mitarbeiter spricht für ein skalierbares und margenstarkes Geschäftsmodell.
- Ein niedriger Wert kann auf arbeitsintensive Prozesse oder geringere Wertschöpfung hinweisen.
- Besonders hilfreich beim Vergleich von Tech- vs. Industrieunternehmen.
Minerva Neurosciences Inc Aktie Analyse
Analystenmeinungen
9 Analysten haben eine Minerva Neurosciences Inc Prognose abgegeben:
Analystenmeinungen
9 Analysten haben eine Minerva Neurosciences Inc Prognose abgegeben:
Minerva Neurosciences Inc Events
🇩🇪 Neu: Alle Transkripte jetzt auch auf Deutsch verfügbar!
Abonniere Premium, um Transkripte und KI-Zusammenfassungen auf Deutsch zu lesen.
Vergangene Events
|
NOV
12
Special Call - Minerva Neurosciences, Inc.
vor 10 Tagen
|
|
FEB
3
Special Call - Minerva Neurosciences, Inc.
vor 10 Monaten
|
aktien.guide Basis
Minerva Neurosciences Inc — Special Call - Minerva Neurosciences, Inc.
1. Management Discussion
Good morning, everybody. It's really a pleasure and honor to have you here on behalf of the Minerva team. Most of my colleagues are here, so after these presentations, when we have something to eat afterwards, don't hesitate to go to see them, to speak with them. It's already an honor to have you here, to really, I think, present you something which is very important. As you know, since 70 years, people have tried hard in order to improve negative symptoms of patients suffering with schizophrenia. I think here today, we have now roluperidone, which is really, really creating some hope for patients. As you know, we are all here in order to come up with better treatments for patients. This is what we will go through today, to give you an update about where we are and where we are going.
And if it is moving, it is moving. Because we are a public company, I have always to show this slide. But I think it's just to mention that we are a public company, and if you want to know more, you have to go to our SEC filings. I have really the great pleasure to have with us 3 persons who have been extremely important for the space. So I have the honor to have Dr. Strauss Greg, yes, because we are working together since quite long, yes, so allow me to call you Greg, yes.
But Greg, you will see, has worked on our data, has analyzed our data, and he has obviously a very broad knowledge about the space. I will not go more into the details because his CV is too long, and he will present his research when he will speak.
The second person could not make it today. It is Dr. Brian Kirkpatrick, and Brian will also speak. Brian is really, I think this is really amazing because Brian is really, really an incredible researcher, but he kept really the contact with patients. He sees patients on a daily basis, and he will tell us about how his patients are looking like, how he sees his patients. I mean, we are targeting with roluperidone in his clinical practice.
Last but not least, we have Dr. Correll, yes, and Christoph is, as you know, no need to present him. He's an amazing person, and he has really contributed a lot to the space. So we will have obviously a Q&A session, so you can ask all the questions to my 3 colleagues here speaking. What we will address today is a quite large program, yes.
First, I will give you a refreshment about roluperidone, where we are with roluperidone. Also, a quick update on the C19 study because the study is ongoing. And afterwards, I hand over to Greg, to Dr. Strauss, who will speak about how important primary negative symptoms are. Yes. We're not going into the details about primary, secondary negative symptoms because Dr. Strauss will speak a lot about it, and he will explain how important they are in order to give some hope to patients. Dr. Kirkpatrick will speak about, again, as I said, his view on our patients, why these patients are not keen to relapse or have limited relapses, and how he sees his patients in his clinical practice.
I will go quickly through some new analysis because we continue to work on our data, just to better understand the data, to better characterize the patient population, to better characterize roluperidone. You will see we have quite exciting data. We have here in the room Jonathan Rabinowitz and Michael Davidson, who have worked on this. If you have questions, they are more than happy to answer the questions. Afterwards, I will conclude with giving you a flavor about what is a market opportunity. Afterwards, we open for Q&A.
I wanted also to mention that we have the chance to have my friend, Frank, who is here, yes, because Frank has been from the beginning of this journey. He is really guiding us through how to bring over the message to the FDA, to the regulator, of this paradigm shift, yes, because we are speaking here about a paradigm shift. I hope that at the end of the presentation, you will see that indeed what we are doing here is a paradigm shift.
As you know, when you are changing something in clinical practice, when you are coming up with new ideas, it is always a little bit challenging, but we are getting there because I think roluperidone could really be the first drug approved for negative symptoms.
So very quickly, a few words about what we are doing here. Just to reemphasize the fact that negative symptoms are really central. It is really central when we are thinking about giving a solution or treating or providing a treatment for patients with schizophrenia. I will not focus on all this primary, secondary negative symptoms because I think Greg will cover this much better than me. I wanted to focus just on the figure on the top right, by the way, published by Dr. Correll.
And just to mention that, and it is maybe obvious for everybody, but it is important, you have 3 types of symptoms when you are dealing with patients suffering from schizophrenia. You have the positive symptoms, materialized or shown by these green lines. And you have some acute phases of positive symptoms, what we call relapses of positive symptoms. And afterwards, when the disease is aging, these positive symptoms are less bothering, are less frequent, are really no longer really a big problem.
This is what we are currently treating with antipsychotics, yes? We are really focusing on treating positive symptoms. You see that we have 2 types of other symptoms, the cognitive deficit, which is materialized with the blue line here. This is a type of symptoms which are present all along the life of the patient. And we have negative symptoms in the brown line. Again, you will hear a lot about negative symptoms. But just what I wanted to mention on this slide, look, what Christoph put is a level where disability starts to kick in, yes? And when you see when disability starts to kick in, it is really when negative symptoms are becoming a real problem.
Really, I think it is very clear now to everybody that if we want to give a chance for patients to have a decent family life, to have a small job, we need to find a solution for negative symptoms. Just to make my case here, so that we -- we know very well, it is very well described in the literature, and there are some references here at the bottom. It is really negative symptoms, not the positive symptoms, which are really the primary drivers of the disability in patients.
So this very schematic way to present things, it is clear that if you are able to improve negative symptoms, probably you are able to improve the daily functioning of these patients. You will see that in our studies, we have really always measured the daily functioning using a scale which is called the PSP scale, and obviously the improving quality of life.
I think what speaks very well here, and I am always taking this example, it is now 70 years or so that we have antipsychotics. And again, don't take me wrong, antipsychotics are very important, yes? They are very important in our ammunition in order to help these patients. But when you are looking to how many patients have a job, nothing has changed since 70 years, yes?
So -- and when you see that 80% to 90% of these patients have no job, compared to 4%, 5% to normal people, definitely, I mean, there is something which has to be done. Again, probably improving negative symptoms, but probably also improving primary negative symptoms is definitely important. Now, coming to roluperidone, yes? Slide shows up, it takes a little bit time. This is the pharmacology of roluperidone, and I wanted just to give you the rationale how we designed roluperidone.
The first objective was to get rid of direct dopamine blockade. This was the first objective because we know that blocking dopamine is very important for antipsychotics to help to treat an acute episode of psychosis or positive symptoms. But we know also that by doing so, you are inducing a lot of side effects. And you are always forgetting sometimes the side effects, but when, I think Michael showed me a recent study, the reason why patients are really willing to stop the treatment is because they are bothered with side effects.
Obviously, they have also the psychotropic effects, but they are really bothered with side effects. So it is really a problem. Roluperidone has no direct blocking effect on dopamine. It is definitely modulating dopamine, and I will not go into the details because it would be too long. But definitely, it is not blocking dopamine.
The 3 targets we have here is serotonin. We are targeting the sub-receptors, which is called the 5-HT2A receptor. It has an antagonistic activity there. The sigma2 receptor, which is a less known pathway in the brain, but definitely, in my opinion, and based on my clinical observations, developing quite a lot of drugs in my life, the sigma activity is probably one of the key drivers of explaining why our drug is improving negative symptoms.
You will see probably primary negative symptoms, and afterwards, you have also an alpha 1-adrenergic activity. So it is always difficult to say this target is doing this, but I think the combination of the 3 targets is definitely explaining the uniqueness of roluperidone.
And last but not least, we have done a lot of work to better understand what is going on also, for example, in terms of nerve growth factors. And for the moment, it is preclinical, but I mean, it's very, very compelling data. We can demonstrate that roluperidone is inducing a huge increase in transcription of BDNF and GDNF, and also the release of BDNF and GDNF. Think one second, I mean, these nerve growth factors are really, really important in neuroplasticity, to restore neuroplasticity. But this is what is about roluperidone, and it has been designed on purpose.
Now, let's see if, I mean, all these hypotheses are translating into what we have seen in clinical practice. Here, it's very summarized, just because, I mean, the objective is not to go through all the data. It's more important that my colleagues are speaking afterwards. What you can see in terms of efficacy, so in all the 2 studies, we have run 2 studies, which one is called C03 study, the other one C07 study.
We have measured negative symptoms using the PANSS scale, which is a gold standard. When you're looking to the negative score, which has been proposed by Professor Marder, which is called the NSFS score, you see that the first study, the C03 study. No-brainer. I mean, 64 milligram showed a very, very strong difference compared to placebo after 12 weeks of treatment in monotherapy. Keep in mind that here, the patients are not staying on antipsychotics. These are really treated in monotherapy for 12 months. What you can see is that in the C07 study, we still have for 64 milligram, which was the highest dose we tested, a p-value, which is obviously going down because a larger study, more clinical sites, but we have still a p-value.
And what we also measured, because this is important, and we will hear a lot about functioning, we measured functioning using the PSP scale. What you can see here, again, in the two studies, we could demonstrate that indeed, looking to daily activities, because PSP is a very practical scanner, so looking to daily activity, indeed, you can see that these patients are, once they're improving the negative symptoms, they're also improving their daily functioning. And obviously, last but not least, what is important, is this drug safe in terms of relapses, when you give it in monotherapy? Because again, the paradigm shift here is to say there is a subpopulation who does not need continuous treatment with an antipsychotic. Obviously, the pharmacology of roluperidone might help, but what happens in terms of relapses?
The green boxes or the green bars, you can see, these are the results we obtained in terms of relapses in the 2 studies we have run, the C03 study and the C07 study. You can see this is over 12 weeks plus 24 weeks for the C03 study, and plus 40 weeks for the C07 study. And Jonathan did a comparison by selecting from a database, which is called the CATIE database. I think it's familiar to everybody. It is the largest database which has been generated in the U.S. with antipsychotics. He extracted the patients who have the same eligibility criteria as the one we have in our 2 studies, and you can see what is the relapse rate you see in patients who are getting antipsychotics.
It's not the final say here, but I mean, it's clear that the patients we have recruited in our studies and the patients we are currently recruiting in our C19 study seem to be less keen to relapse. And we'll hear much more about it, why we might think that this is the case. So this is a study. So I think everybody has seen the study design, but this study is really coming out of all what we learned from the previous studies with in-length and very productive discussion with the FDA. And I have to say that we had really, really good interactions, good advice, and I think it's fair to say that this is somehow a consensus of what we have to do here.
So the first thing we have to do, because keep in mind that this is a large patient population we are addressing, what is called Phase A of the study, the first 12 weeks, you see, this is to really confirm what we have seen in terms of efficacy with the 2 previous studies. So big difference here compared to the 2 previous studies is that we are focusing on 64 milligram, which is the dose for which we are seeking an approval, and we have no longer 32 milligram in this phase.
So the objective here is really to demonstrate that indeed, using the NSFS endpoint, so the negative symptom endpoint we have used in the previous studies, we show a p-value between placebo and treatment at 64 milligram. What we call Phase B, this is really different from what we have done in the 2 previous studies.
In the 2 previous studies, the patients were allowed to go into an open-label extension, so everybody was switched to treatment. In this case, and this is really something which has been discussed with the FDA, and I think it's very important. Also, it will be purely descriptive because the number of relapses we have does not allow you to do any formal statistical analysis. It will be purely descriptive, but it's a comparison between our patient population, the patients we have recruited in our studies, the patients we are recruiting in the C19 studies, study, sorry, once they are receiving an antipsychotic, we will check the relapse rate, and we will compare it to the relapse rate we see with roluperidone.
This is important to reassure the patients, to reassure the prescriber, to reassure the agency that indeed, I mean, there is nothing severe which happens when you take off this patient population from antipsychotics. So we will hear much more about this from Dr. Kirkpatrick. So this is basically the study. I will not go into the details of where we are with the study. We are really enrolling. The study is going according to plan, and as we have disclosed, we really hope that we will have the results in the second half of next year. Today, definitely, we are on track to have the results coming out. I'm speaking obviously about the first 12 weeks, so about Phase A, during the course of second half of next year. I will be not very long on this slide, just because this is too complicated, too busy.
But it's just to say that the study design we have implemented here is not just because we wanted to do it in this way. It was really done by really thinking what we are trying to achieve here. First of all, we wanted to demonstrate that we have an effect on primary negative symptoms. So on primary, meaning disease-related negative symptoms. And -- and so here, you need to avoid patients who are fluctuating too much. And so we are looking to stability of these patients over the last 6 months before they're candidates to the studies. They need, obviously, to have negative symptoms which are impairing in order to be part of the study.
But just to mention that you go to the literature, and I'm using the word Mike is always telling me, and he knows the literature in and out, Dr. Davidson, it's a [ graveyard ] to put drugs on top of antipsychotics because you're blocking dopamine, and the things they like you to improve, negative symptoms, is difficult. I'm not saying that it is not possible, but we have decided to focus on a subpopulation where we think that there is more stability in order to really demonstrate that first, roluperidone has an effect, sorry, on primary negative symptoms. When the drug will be approved, we can really think about moving forward.
So when you're looking to the conclusion of all this work, and even there was a committee at the ISCTM meeting who was working on study designs, I think it's fair to say that probably the best study design is monotherapy, a long period enough, stable patients, and because there is no approved drug in terms of negative symptoms, the comparator is placebo.
A last thing, which is coming on the last slide before I hand over to Dr. Strauss, I wanted really to make something very clear. Because I'm obviously reading all the reports, I'm reading all what is published, and a lot of people say, "Okay, I have an effect on negative symptoms." This slide, I think, is to explain that you have 2 things. You can improve primary negative symptoms, so this is a brown line, yes?
Basically, you're reproducing the brown line, which was also in the slide from Dr. Correll. So this is what we call, and technically, this is a trait marker. So this is a marker. These are symptoms which start very early on and are present all lifelong of the patient. And afterwards, you have what we call state markers. These are markers or symptoms when you're looking to the patient today, yes? So one day, the patient can show some depressive disorders. One day, he can be bothered with extrapyramidal symptoms, his motor symptoms, because his treatment is not completely adapted. And sometimes these patients have an acute relapse of positive symptoms, which is a green light at the bottom. When you bring down from these acute episodes a patient, this is what we call a pseudo-improvement, yes?
So you are improving, or you are bringing back the patients to the level of their primary negative symptoms, of their disease negative symptoms. So I think the only way to claim that you have really an effect on primary negative symptoms is to do what we are doing, stable patients, long-term effect, and all the rest is hope maybe to improve negative symptoms. But to bring someone down from an acute episode is a pseudo-effect, a pseudo-improvement of negative symptoms. It is very important, so that we understand about what you are speaking. I think it is time now to hand over to Greg.
Good morning, everyone. It is a pleasure to be here. I am Dr. Gregory Strauss. I am a Professor of Psychology and Neuroscience at the University of Georgia, and my research over the last 20 years or so has focused on negative symptoms, in particular the phenomenology or how we conceptualize them, developing new assessments for negative symptoms, understanding their mechanisms from a neurobiological perspective, and of course, working on new treatments. And there is also always a beautiful irony of having negative symptoms be your scientific expertise. I am very motivated to study the lack of motivation. I enjoy studying the inability to experience pleasure, and of course, I am excited to talk to you about some of our new work on this today. As Dr. Luthringer set up so beautifully, negative symptoms are heterogeneous.
In other words, you can have 2 patients with the exact same score on a negative symptom clinical interview scale, like the PANSS, for very different reasons. For example, they may both have a score of 20 on the PANSS. One patient may be predominantly apathetic. We call this primary negative symptom. It is something that is assumed to be a direct manifestation of the illness of schizophrenia itself.
You can have another patient who looks identical on paper, but their negative symptoms are secondary, the result from other factors. And that this is not a concept specific to negative symptoms or even to psychiatry. It is known throughout medicine. Give you a brief example. Last summer, took my daughters to Orlando. We went to Disney World. They were very excited until we got home to this rental house at the end of the first night.
My younger daughter, seven years old, wanted to go downstairs and get a drink. Daddy went downstairs with no contacts in. I went one way, my ankle went the other way. Snap, snap. Later, I cannot walk for a few days. Fast-forward a couple of months, I go to the doctor and I say, "My knee is hurting." And looks at the knee, nothing is wrong with the knee. She says, "This is secondary. You need to improve your ankle. You have not rehabilitated your ankle. You went back to your normal level of exercise too quickly."
In psychiatry, it is a similar idea. The idea is that there are common secondary sources of negative symptoms. Screen went forward on me. There are several common secondary sources of negative symptoms, and 2 of them are depression and anxiety. For example, someone may be incredibly sad, feeling worthless. They may have sleep problems.
These may cause them to have a lack of recreational activity, goal-directed social behavior. Another person may be very worried. They may be very tense in their expression of emotion in the face and look very blunted. They may be so concerned about the things they are worrying about that they do not seek out social or goal-directed activities. This is very different from someone with true or primary negative symptoms.
These patients will not feel depressed or anxious regardless of what is happening to them, regardless of the stimulus. For example, a case where a patient's brother passed away. They were living with the brother, sharing a room with the brother. They did not feel sad. They did not feel depressed at all after losing the brother. Anxiety, same thing. Another patient with this primary negative symptom profile was held up at gunpoint. Remarkably terrifying experience for anyone.
Did not feel fear in this situation. No anxiety, right? This is a very different profile, this secondary negative symptom profile, than what happens with primary negative symptoms. Similarly, positive symptoms can induce negative symptoms as a secondary cause. For example, hallucinations. Someone may hear a voice telling them, "Don't get up off the couch or the FBI will come and chop your legs off and you will die."
They sit on the couch, they do not engage in activities, and they are behaviorally delusions. Same thing. They may be paranoid, thinking others are out to harm them, so they withdraw socially as a protective mechanism. Or they may be so disorganized in their thought that they cannot execute goal-directed activities to engage in motivated behavior. This is not a primary negative symptom. People with primary negative symptoms have very low levels of positive symptoms, low levels of hallucinations, delusions, disorganization.
So without having any of those positive symptoms at a severe level, they still have negative symptoms. They still withdraw socially. They are not interested in the social interactions. They could take it or leave it. They do not feel lonely even though they have spent the majority of their time alone during the day, right? This is a very different profile. Similarly, medication side effects. Someone might be sedated due to the effects of their antipsychotic. This may cause them to have less behavioral activation.
Someone with primary negative symptoms, they continue to show the lack of behavior even in periods where they are medication-free, right? So their negative symptoms persist even into these medication-free periods. So treating, importantly, there are a couple of very critical things to know about this primary-secondary distinction. The first one is primary and secondary phenotypes have distinct underlying mechanisms.
We have estimated that primary negative symptoms largely result from disrupted cortico-striatal circuitry that is driving this apathetic profile. Secondary negative symptoms, on the other hand, have different underlying biological factors that travel with the secondary sources. They travel with mood, anxiety, positive symptoms, et cetera. Because of these distinct underlying mechanistic profiles, point number two is really critical.
Treatments targeting secondary sources often reduce negative symptoms in patients with secondary phenotypes. In other words, if you have a patient who is depressed, treat the depression. If their negative symptoms are driven by anxiety, give them an anxiolytic. Not in every case, but a good percentage of the time, the negative symptoms will improve as these secondary sources improve. This is the pseudo-specificity that Remy was talking about a moment ago, right? The negative symptom effect is essentially a byproduct, if you will, of improving these secondary sources.
The third point is that treatments targeting secondary sources do not reduce negative symptoms in patients with primary phenotypes. Treating patients with a primary phenotype with antidepressants, anxiolytics, will not improve their negative symptoms. It is the wrong mechanism. Their mechanism is distinct and not being hit by that compound. Fourth, treatments targeting primary negative symptoms are not expected to reduce negative symptoms in patients with secondary phenotypes. Essentially, again, another mismatch between mechanism and mechanism of action of the drug and the underlying mechanism in a patient. So what does this tell us? The treatment of primary negative symptoms is the holy grail. This is something that has not been addressed in the literature to date. There are strategies for addressing secondary negative symptoms, but not primary.
They are critical because, of course, for many reasons, but they are tied to lower rates of recovery, poorer functioning, lower well-being, greater stress on the family and caregivers. This is really, as others have termed, the holy grail of psychiatry, is to find a treatment for primary negative symptoms. Of course, the critical question becomes, is roluperidone doing that? The short answer is yes. On the screen in front of you, what you see is data from a probability calculator that estimates the extent to which someone's negative symptoms reflect primary or secondary causes. If you look at the figure on your left, primary negative symptoms are displayed. What this is an algorithm we developed called the Primary Stability Weighted Score.
And what this is essentially an estimate of the severity of someone's primary negative symptoms, weighted by how persistent they are over time, from baseline to the end of the study. Here, higher values mean that the negative symptom is more primary and more persistent, right? What you see here is that placebo has higher primary and persistent scores than roluperidone. This is exactly what you would want if the drug is treating primary negative symptoms.
Placebo is going to be consistent across time. Their negative symptoms are not changing. They are primary. They do not fluctuate. They are enduring trait-like features. When given roluperidone, the patients who are responding are the ones with this primary phenotype. Their negative symptoms become both less severe, the primary negative symptoms become less severe, and less enduring. You can see that indicated by the lower scores there for roluperidone than placebo.
Now if you are not familiar with looking at these types of charts, a handy way to know if something is statistically significant is to not just compare the height of the bars, but also to look at the overlap in the standard error bars. You can see the error bars here have minimal, or potentially no overlap, and that is indicating a greater likelihood of statistical significance.
You can see in this particular metric, the p-value is 0.03, so less than 0.05. In contrast, the secondary score did not significantly differ. You can see here the p-value is 0.61. Now the secondary score is a little bit different. First thing to know is that it is on a different scale than the primary score. The figure is also very zoomed in, so it is also on a the axis is a little bit centered differently.
But what this scale score represents is essentially the likelihood that someone's negative symptoms are driven by secondary factors like anxiety, depression, paranoia, hallucinations, and how dynamic they are over time. Because remember, secondary negative symptoms are transient. They fluctuate a lot as those secondary sources vacillate across time. They're inherently unstable. So this score weights not only how secondary the patient is, but how inconsistent or unstable their scores are across time. And what we see here is that placebo and roluperidone do not differ, and that's suggesting that the drug is not having an effect on secondary negative symptoms, but of course, it is on primary. And again, this is really the holy grail of psychiatry, of showing an improvement in primary negative symptoms. Now, importantly, that's not a given.
I would argue that prior studies, if they have reported an effect on negative symptoms, many of them have, if not all, have been really driven by pseudo-specificity and these improvements in secondary factors. So this is something that is really an important finding. Now, another key thing that we have found with roluperidone is addressing what is driving the effect, and I don't mean at a neurobiological level. We know the components of the drug.
I'm talking about in terms of a symptom network level interaction. Many clinicians think of individual symptoms as being distinct entities, but that's not correct. Just like almost any other element of the environment, things interact. Symptoms can interact. For example, why would someone not show emotion in the face? Why would they not speak? Why would they not engage in social activity? Maybe they don't enjoy those things.
Maybe there's an underlying factor driving. Maybe it's a hedonic deficit. Maybe the way to treat that deficit would be to hit that component, right? And you would see a cascading effect temporally where all the other domains would improve. You could make another hypothesis that maybe it's social functioning. These are people who've been devoid of social interaction for years, and maybe the drug achieves its effect by making them more social, so then they have more opportunities to speak, become more expressive, more motivated in general.
So there are many possible interpretations. The one we hypothesized, however, was neither of those. It was that the drug achieved its effect by hitting a key mechanism of avolition, or a reduction in motivation, right? So what actually was found here using these network analytic approaches is that when the drug improved the negative symptom constellation, it first hit motivation.
Once motivation improved, there was a subsequent cascading effect across time where all of the other domains improved. So motivation is highly central to the improvement of the entire negative symptom constellation. And this was data from the C03 study. We subsequently replicated this effect in the C07 study. This is a similar but more recent network analytic approach and intervention network analysis.
These algorithms are changing, like, every 6 months, there's something new out there, so we applied one of the newer ones. And what we found is that there's actually a direct effect of the treatment on the PANSS item most similar to avolition, which is called emotional withdrawal. So in other words, the drug effect was hitting this item related to avolition, and again, it produced this cascading effect where you saw subsequent improvements in the other negative symptoms.
A replication of the Phase II C03 study findings. Now, hang with me. Why does this matter? Why do these network approaches matter? Who should care about this? I would argue that these are perhaps some of the most critical findings. Why do any of us do anything we do throughout the day? Our motivational system is functioning. Why do you change your clothes? Why do you go to work? Why do you have romantic relationships, friendships, write checks? Motivation is a critical component of this. Without it, these activities become much more difficult to activate. One reason that this network finding matters is because of this graph here. In both the C03 and C07 studies, what you see is an improvement of functioning, of role and social functioning for roluperidone compared to placebo.
So it improved these aspects of daily life, such as doing chores, getting to your appointments, having friendships, romantic relationships. And this is not a given, right? It is possible to change motivation but not change these critical behaviors. It may be that someone wants to do them, but they do not do them in the real world. That was not the case here. With roluperidone, you see that with this effect that happens on motivation, there is a subsequent effect on functional improvement. So motivation may be important to change because of its critical relationship with functioning. To give you an easy way to remember this, what is the importance of avolition or motivation here? Why does the entire constellation of negative symptoms improve?
You change motivation, you make people want to speak more, you make them more likely to be expressive, you make them more likely to interact socially, to engage in pleasurable recreational activities. Interestingly, you can also improve their cognition. One of the key findings previously published on roluperidone is that it also improves basic neuropsychological test performance.
And motivation is also a critical aspect of cognitive impairment. You have to be motivated intrinsically to do well on these tests to have a good performance. So changing motivation may be critical. Improving cognition in tandem may actually also be critical for improving motivation. It may allow you to have better executive functioning to execute goal-directed activities better. So why is roluperidone important from a clinical perspective?
It is improving all of these aspects of negative symptoms that are critical through this effect on motivation that has the subsequent improvement on the 2 critical unmet needs in schizophrenia therapeutics, cognitive impairment and functional outcome, right? These are really important for improving the quality of lives that patients have and making them more likely to recover and do better in life.
So again, primary negative symptoms are really important as one take-home message, and roluperidone is indeed changing primary negative symptoms, but not secondary. It is achieving this effect through a direct improvement on motivational processes that are important for improving functioning. And I will stop here and pass it back to Dr. Luthringer.
Thank you so much, Greg. Now it's my pleasure to introduce Brian. Brian is sitting in a very nice location. Brian, the floor is yours. I don't know, do I have to change the slides? Okay. Brian, you tell me when I have to change your slide.
Thank you. I'm Brian Kirkpatrick. I'm a professor in the Psychiatric Research Institute of the University of Arkansas for Medical Sciences, and throughout my career, I have focused on research and clinical care on people with psychosis. Next slide. I'm going to be talking about clinical issues for patients with primary negative symptoms, give you some more idea of who these patients are, then talk about whether monotherapy is safe or even beneficial for some people, and what are the consequences of treating negative symptoms.
Next slide. This is a very distinctive group of patients. There's been a lot of research on those patients whose negative symptoms don't appear to be due to anxiety, depression, hallucinations, disorganization, and so on. In Europe, the usual term is predominant negative symptoms, and in the U.S., it's more often referred to as primary or deficit schizophrenia.
In a clinic, they usually receive less attention than other outpatients. They kind of fade into the background a little bit, unfortunately, partly because their hallucinations, delusions, disorganization of speech, and agitation are mild or absent, and these are things that clinicians typically worry about and routinely assess. Plus, by definition, as a group, they simply have less motivation, avolition. They complain little. In the U.S., if they're placed in a group home, they tend to stay there.
Plus, another factor for there being less, people pay less attention to them is, there's an absence of established treatment. Clinicians are pessimistic about their prognosis and pessimistic about interventions. All this is unfortunate because they have poorer function on average than do people who don't have primary negative symptoms.
Next slide. I'm going to show you some evidence of the importance of these primary negative symptoms for function. Patients in an outpatient clinic were rated for the presence or absence of primary negative symptoms, and it was a categorical rating, present or absent. Then five years later, they were assessed by other raters who were blind to the study hypothesis of function.
The primary/secondary categorization that had been made 5 years earlier explained variance that was not accounted for by other symptoms. What you see on the p-values is that after accounting for variance from negative symptoms broadly defined, for instance, on the SANS or the PANSS, or the severity of hallucinations and delusions, and of disorganized speech, of demographic features and age of onset, primary negative symptoms still had a significant relationship to poorer function.
Next sentence, sorry, next slide. So, what about monotherapy, which is the design for the roluperidone studies? Antipsychotics decrease the number of relapses and hospitalizations in people with schizophrenia. So, that raises questions about the use of roluperidone as a monotherapy, as it's not considered an antipsychotic. And as a group, antipsychotics are associated, as you've been told, with increased risk of weight gain and its consequences, including hypertension and diabetes, movement, and also risk of movement side effects, tardive dyskinesia, abnormal involuntary movements, restlessness, which can really be miserable for someone, and stiffness. They may feel sleepy during the day because of antipsychotics. And there was mention before of elevated prolactin, hyperprolactinemia. This is a hormone, a normal hormone that everybody has, but when it's elevated, it has certain problems, especially for women, and other problems for men.
And antipsychotics don't improve primary negative symptoms and can worsen secondary negative symptoms, and there's direct evidence on that latter part, that latter statement. Next slide. So, people who stop taking an antipsychotic have been studied for many years, and the broad conclusions are, yes, they have more relapses. But if they are having some contact with a clinic, serious consequences are rare.
Also, some people are able to enter treatment because we'll accept that they will only take antipsychotics when they have increased symptoms. And patients also often have an increase in symptoms, such as non-specific things like depression, anxiety, sleeping more, before there's an increase in hallucinations and delusions and so on. What's interesting about this in part is that, in my experience, patients tend to have their own idiosyncratic warning signs. Some people consistently become anxious. Some people consistently simply become withdrawn.
So, they and their loved ones often notice these early changes in time to stop the worsening of psychotic symptoms. Next slide. Well, before I go on, let me just tie together a little bit more of a sense of who these folks are. The kind of thing that you might hear from family members is, "You know, my son isn't worried about the FBI anymore, and he doesn't seem to be hearing things or seeing things anymore, but he stays in his room all the time.
He says he's not depressed, he's sleeping okay, he's eating okay, but he's just not doing anything, and it doesn't seem to bother him that his life is really pretty boring." That's an example of things I've heard. So, now I'm going to give evidence that patients who meet Minerva entry criteria simply have a low risk of relapse independently of treatment.
I'm going to give you evidence from the CATIE study again, and from Minerva's C03 and C07 studies, the Phase II-B and the Phase III studies. Also, data from a meta-analysis of relapse in patients who have been in studies of stopping antipsychotics, and also what is known about baseline symptoms. We'll kind of take apart the symptom group, the symptoms that are used to define the Minerva entry criteria. We'll look at baseline symptoms and subsequent risk of relapse. Next slide. So, Dr. Luthringer mentioned that there was a difference between patients in the CATIE study who did and did not meet the Minerva entry criteria. So, the CATIE study had almost 1,500 schizophrenia patients who were recruited from 47 U.S. sites, and they were then randomly assigned to one of five antipsychotics and followed longitudinally.
What you see on the graph to the right is time to relapse. So 100% of patients at the beginning, those who met criteria and those who did not meet criteria, had not relapsed by definition. They were stable. What you see is that very quickly a difference appears. There are fewer who have remained without, I am sorry, there are more who have remained without relapse if they met the Minerva entry criteria.
Their last data point, they had about 68% or 69% who continued not to have a relapse, whereas it is more around 58% or 59% in those who did not meet the criteria, and this difference was significant. In this study that is not conducted by olanzapine, that was published in 2005, you see that there is something about this group of patients that seems to confer a lower risk of relapse.
Next slide. Now we are going to bring in data from a meta-analysis of drug discontinuation trials, and they were treated with placebo or an antipsychotic, and there were 9,000 patients in this meta-analysis. What you see here are the data. The meta-analysis presented up to three months and then up to 4 months or 6 months. That is why you have those two time points.
What you see is that the two roluperidone studies that are up at the top, C07, C03, and the patients who were from the CATIE study who met the Minerva entry criteria, but were all on an antipsychotic, are all up at the top. The CATIE positive folks on drug, not going to push this too hard because not necessarily all the P values are significant, but you see that they have lower relapses.
If you compare those three studies from patients on placebo from a meta-analysis, there is a very big difference. We are comparing with C07 and C03, we are comparing patients who were on monotherapy with roluperidone to patients who were drug-free and on placebo. They were C03, C07, and the bottom graph, the black dashed line. None of them were on antipsychotics. The CATIE study patients were. Next slide. How about if you break it down into specific symptom groups? These are 5 studies from 2 repositories, the YODA and Vivli repository of clinical trials. Now the Minerva entry criteria define a group. By definition, they have low positive symptoms and high negative symptoms. What you see on the chart is that, look at the top line.
That is PANSS positive symptom factor, and compared, the greater the difference between patients with higher symptoms who are otherwise similar to other patients in the same studies, the greater the impact on risk of relapse. For positive symptoms, it increases. You have this stepwise increase the more they deviate from otherwise similar patients. Whereas with negative symptoms, the more negative symptoms they have, the less the relapse rate.
Low positive, high negative symptom profiles, which is the patient group that we have been discussing, they are less likely to relapse. Given this, patients in Minerva's clinical studies should have a low risk of relapse. It would have been surprising if they had not. Next slide. This is from a similar finding from an Italian cohort of 24 university psychiatric clinics and mental health departments. It is a 4-year follow-up study.
On the graph, what you see is 4 groups, and the measurement there, as you can see on the axis, is PANSS negative symptom factor score. So from seven to 16, all the way up to 28 to 48. Again, there's a stepwise decrease in risk of relapse over this 4-year period. The higher your negative symptoms, the less the relapse. Next slide. What does this relapse evidence mean? Well, there's a consistently lower relapse risk in this population across decades, across national borders, across different studies, across various definitions of relapse, including hospitalization. So this provides evidence for not only the existence, but also the validity of this group of patients with this symptom profile. And for this group, roluperidone has a reasonable risk-benefit ratio. Finally, monotherapy with roluperidone is an example of precision medicine. Next slide.
So you have a pharmacological treatment that decreases negative symptoms. There's an important issue to keep in mind clinically for these patients. Many of these patients have had years of relative social isolation and poor function, and they may not have much confidence or much skill with regard to self-care, relationships, and employment. Despite that, in the 12-week intervals, roluperidone patients have shown improvement in really the most widely used function scale, strongest function scale, the Personal and Social Performance scale, which is a measure of function in the C03 and C07 studies.
An important consequence, though, of successful treatment of their negative symptoms will be that they will be able to respond more to the evidence-based psychosocial treatments, which, by the way, have pretty good effect sizes. So they should have the opportunity to continue to have further improvement. Next slide. We are back to Dr. Luthringer.
Thank you so much, Brian, for all this important data. Yes, I think what Brian is really addressing is we are more and more working on this, but we are more and more characterizing this patient population. I think this is extremely important, yes, when the drug will be available, that the prescriber will understand which patients would benefit from this treatment. So, I think we are making a lot of progress, and I have to say that at Minerva, we have put together an outstanding SAB with these people who are speaking today, but with other persons who are really bringing a lot of their knowledge in order to really be ready to better explain how this treatment should be administered when it will be available to patients.
So what I will speak about just quickly, yes, before handing over to Dr. Correll to finish off, is just some analysis we have done, continuing to try to understand and to show the uniqueness of the effect of roluperidone. I will go through 3 different things. The first one is a Bayesian analysis we have done with our data. I will come to this in a second. And the other aspect is what we call the global statistical test. Last but not least, something which is very important is afterwards to compare how many patients are responding to our drug compared to placebo. And this is obviously what usually the FDA is using.
They say, "Okay, the drug is improving, I don't know, positive symptoms, and you have 30% of the patients responding with treatment versus whatever percentage under placebo." I will focus on these 3 things very quickly. So why do I show you the Bayesian analysis? So as you know, what you usually have to do is to have two studies, which we call frequentist analysis. You are analyzing the data in a frequentist way. And so in the case of frequentist analysis, you are just putting each study as a standalone observation. Yes? Each study needs to show a p-value, and you don't take into account what you know already about the study, about the drug, excuse me.
And interestingly enough, I think the FDA starts to recognize that, yes, this is still the gold standard, but probably we would benefit by learning from what we have known before we run the study from the drug. This is interesting enough, the FDA put out a guidance in January 2026, in order to really explain how you could apply the Bayesian analysis. What we have done here is to, based on a very positive study, obviously the C03 study was a very positive study, we looked how much you have to borrow. This is about borrowing, about what you have learned from the previous study, in order to make the C07 study a very successful study.
What you can see very nicely for the primary efficacy endpoint, which is NSFS and PSP, what you have to borrow to really make the Bayesian analysis highly positive is extremely limited. And clearly, we discussed this in length with Frank, when the borrowing is below 20% or 30% or even 40%, you can really come to the conclusion that your drug has a real effect.
In our case, you have to borrow less than 20% to make the things highly positive. I do not take more out of this. I am just saying that, if you are applying Bayesian analysis, you can come to the conclusion very easily that the roluperidone is working. It is just another way to look to our data and to come to the conclusion that indeed, roluperidone is working not only on negative symptoms, but also on functioning.
Now, the global statistical analysis is an interesting one, yes, because global statistical analysis is, as you can see, it is to combine endpoints into a single test, while correcting for correlations. So really, I think this is what is important. Usually what you are doing when you are analyzing data, you have your primary endpoint, you are looking to your secondary endpoint, and as you know, human beings, we are not completely objective. Yes? This is a way to really demonstrate that indeed, using a very robust statistical approach, that indeed, improving negative symptoms is translating into an improvement of functioning. Obviously when you are doing GST, you have to combine something which makes sense, and here is exactly what we did in the two studies, primary efficacy endpoint and sole key secondary endpoint.
What you can see very nicely is that, for the C03 study, where you have a very, very high p-value in the GST approach, so basically combining negative symptoms and functioning. Look to the C07 study, again, highly significant. So and what matters at the end of the day, indeed, is that patients are functioning better, as we heard from Dr. Strauss. So clearly, I think this is a very nice demonstration that with an objective statistical tool, we are demonstrating that the two things are really correlated, not correlated, that negative symptoms are producing a very strong functional improvement. When you are integrating, obviously, the 2 studies, at the bottom line, the things are staying extremely significant.
I think it is a very objective way to reemphasize what Dr. Strauss was saying, that I think the uniqueness of roluperidone, it is on one hand improving primary negative symptoms, but it is also transforming into a functional improvement, which is, best of my knowledge, has never been really demonstrated. Now, coming to what usually the agency is looking at, yes, and this is what we call the responder analysis.
On the complete left side, this is a classical responder analysis. You are looking to the primary efficacy endpoint, you are looking to the patients who are improving more than 20% during the course of the treatment, and you are comparing this between the placebo group and your drug. What you can see very nicely here is that the patients are treated with roluperidone 64 milligram, it is around 38%, whereas for the placebo group, you are at around 22%.
Usually also, and I am speaking under the control of Frank, when you are going above 30% of responders, I think this starts to speak positively for your study. We wanted to go further down the road in order to better understand the difference between roluperidone and placebo. What we did, and this is the middle analysis, what we did, basically Jonathan, who is here in the room, did, we did an analysis where we were anchoring the primary efficacy endpoint, so negative symptoms, NSFS.
We were anchoring this to CGI-S. It is very well described in the literature that one point improvement or more of the CGI-S is clinically meaningful. Yes? It is really telling you that something good is going on in terms of functional improvement of the patient. Look again, definitely roluperidone 64 milligram is much better than when you are treating your patients with placebo.
Last but not least, we wanted to focus on functioning, yes, and we did this analysis using not the primary endpoint negative symptoms, but PSP functioning. This is on the right side of the graphs on the right side. What is known from the literature, and I think [ Dr. Nasrallah ] published this in length, is that when you have an improvement of more than seven points of the total score of PSP, this is really clinically meaningful. What we did here, because our recent publication showing that, I mean, if you are going to 10 points or more improvement, not only the patients will function better, but, I mean, the likelihood that they might relapse is also reduced. Just to continue to better understand our data.
But so when you're looking to these results, which is very challenging, yes, to reach 10 points, you see again that definitely, roluperidone 64 milligram is doing a much better job than PSP. But to put this into the context, yes, so you see that another way to look to this data is to look to the number needed to treat.
So, how many patients do you need in the treated group to be better than the placebo group? And you see that the numbers for these three types of analysis are seven, eight, and nine patients. It might look a lot, yes, but when you're putting this in the context and you're looking the number of patients, and this is at the bottom right, the number of patients you need for antipsychotics and for antidepressants, we are exactly in the range.
So, just to say that it's always very difficult to say that all this is clinically meaningful, because I think it's too early, because this is the first drug really moving the needle on negative symptoms. But I think all this data really demonstrating that there is a real benefit for the patients who are treated with roluperidone compared to placebo. I have now the pleasure to hand over to Christoph Correll, who is making some emails, but Christoph, you have to speak now. Thank you, Christoph.
Great. Thanks so much, Remy. Thank you all for being here today. I hope this is on. Yes. So my name is Christoph Correll. I'm Professor of Psychiatry and Molecular Medicine at the Zucker School of Medicine at Hofstra Northwell, where I've been for the last 29 years, and I'm also Professor and Chair of the Department of Child and Adolescent Psychiatry at the Charité University in Berlin, where I've been for the last eight years. My work for the last 30 years has focused on clinical work and research in people with mood disorders and psychosis.
And we talked last night about regret, and basically, I have one professional regret. When I started medicine, I was a little naive. I thought I could cure and understand schizophrenia. I now understand this is out of reach. But I have one personal regret, and that is that during my work and work of many others, we have not yet found a treatment for negative and cognitive symptoms in people with schizophrenia, the two drivers of disability. And that's why we're here today, to change that regret.
So let's talk about the negative symptoms, but also where roluperidone, if and when it's being approved for negative symptoms, can go, because these symptoms are not owned by schizophrenia. Our brain has multiple ways of expressing something that is positive, but also something that's missing. And this missingness cuts across multiple disorders. So I see a lot of opportunity for roluperidone to help patients with other disorders where there's a lot of disability. Let's briefly revisit what Greg Strauss has been talking about, the negative symptoms.
The way we currently narrowly define them for schizophrenia, they have to do with two dimensions. One is expressive, where we understand what the patient is maybe feeling and thinking. It's very important for social interaction. That has to do with blunting of affect and also alogia, not talking much. Patients have a hard time connecting with other people if other people can't read them, if they can't express themselves.
What is even more relevant for the functionality, though, is the intrinsic experience of life, and that has to do with anhedonia, not being able to experience pleasure, but then also the expression of that motivation on the social level or other things. Asociality is central. People just sit on the couch, as we've heard. They're not interested in other people, and families beg us to bring their son and daughter back.
They feel their children, their loved ones have checked out. They're just physically there and not much more. This avolition cuts across everything. Families notice when something changes. They just want their loved one to pick up the newspaper again and show a sign of light and interest in life. That's what we're here for. We need to change that. There are different ways of cutting the pie of negative symptoms. Some have even some cognitive aspects in there, because Professor Strauss also mentioned that there's this interaction between cognition and negative symptoms. You can only use your cognitive abilities when you're motivated to do so. But when we looked at multiple studies, the frequency of different dimensions of negative symptoms might be different based on the patient population we're looking at.
But within each study, we could see that the blue is more frequent, then the red is more frequent, then the green. That means we have a lot of social avolition, no matter what the study is. My apologies, so it has to do with the study. But you see that within the red, within the blue, and within the green, we have more social avolition, then with diminished expression, and then inattention, alogia. This social aspect, not being able to motivate yourself to do things, is crucial that we need to address. Because negative symptoms have multiple pathways into eroding people's lives, eroding their social interactions, eroding their aspirations for job, and also for work.
And Freud said, "The two things that are relevant in life is work and love." Those are the 2 things that are undermined by negative symptoms, even more so than by positive symptoms, which we can now treat. As you've seen in the subtype of patients that have little residual positive symptoms, that is not the issue anymore.
This type of precision psychiatry that also Brian Kirkpatrick was talking about is unique. We don't have any psychiatric treatment right now that has focused on a biological and clinical subgroup that is relevant, and that gives us much higher likelihood of success rather than blasting patients with one medication to treatment of patients that have very heterogeneous results and also underpinnings. Again, to just highlight the interaction between cognition and negative symptoms, cognition gives you the ability to do something. It's your capacity.
But without then doing something about it, you are just keeping your capacity floating freely around. You need to have performance, and functional performance has to do with executing this. The execution of your capacity has to do with motivation and seeing also value in doing it. The value has to do with hedonic drive. I can anticipate that things are going to be good. I can enjoy them. That then gives us reinforcing behaviors. We know that people with negative symptoms also have high cost that accumulates.
So here, payers should be very interested in that. We know the interest by the FDA is great because you do not even need to have an extra outcome of functionality. This is a given. Not so much with cognition. With cognition, we need extra measurement of outcomes on the functional side.
But since negative symptoms and functioning are so tightly intertwined, that is not needed. Now, we have seen with the data for roluperidone that PSP was really moving even stronger than the negative symptoms. So we see an agglomeration of the effect on what patients want, what families want, and what regulators are interested in. Now, I mentioned that I am also a child psychiatrist, and I became a child psychiatrist because I wanted to prevent the illness, and that means we are looking at the so-called prodromal phase. It is the clinical high-risk phase where patients do not yet have positive symptoms, but this is loaded with negative symptoms. It is loaded with cognitive symptoms.
While we still need to collect data on that, there is at least a prospect that by treating the negative symptoms early in the illness, we might be able to avert the psychosis from evolving, because there is an interaction between the neuropsychology or neuropathology that is underlying the negative symptoms that might actually secondarily drive the positive symptoms. As we have reduction in functioning in some areas of the brain that have to do with dopamine and glutamate as the final endpoint, there are other areas in the brain that come online in order to compensate for that.
Now, this is future music. One would have to look into this, but it is obviously very, very compelling. Even if patients do not yet have the real risk for psychosis, treating negative symptoms early that are independent of depression will help them even at that stage to function better.
Now, this is a slide that I got from [ RexKako ], like the last one and the next two ones, which really has a lot of text on there, and this should dizzy you because that is the purpose of this. How dizzying is it that the negative symptoms that were defined and we have always been talking about in the context of schizophrenia actually might occur in 18 other conditions? And that has to do with the fact that what we call negative symptoms, this terminology, when you use some other words that have been used in other conditions, actually it converges on the same thing. Has to do with lack of motivation and willpower, has to do with apathy, not being able to get yourself to experience something or express yourself, and it has to do with anhedonia, not enjoying things. And these aspects really cut across multiple domains.
The question then is obviously, where would one put one's emphasis the most? We will get there in a minute. First, some more data that RexKako also put together just to show you that the so-called negative symptoms, which is a group term for problems that is there is an absence of things in the brain and in people's lives, cut across not only schizophrenia, but also major depressive disorder, the ultra-high risk syndrome, which I just mentioned, the risk syndrome for psychosis, bipolar disorder, and it is much higher than in healthy controls. Now, we could say that some adolescents have a little bit of negative symptoms. They have all the capacity and just sit on the couch. That is a prodrome to adulthood, but obviously, we need to motivate everyone to do better and express themselves.
Because especially during early phases of development, when you have learned that you are not able to do certain things, that people don't read your emotions, that you are not connecting, that becomes part of your persona. You don't even expect this to change. You are not really motivated to do things about it because there is no reinforcement. This reinforcement needs to come by lighting the bulb up again and getting patients back into life.
Here you see the comparison of the so-called negative symptom domain compared to people in the general population, and you can see that it really cuts across multiple of these disorders and that there is a big problem with anhedonia and avolition. Putting all of this together, where could roluperidone fit in the clinical treatment paradigm? Now, obviously, it is being developed for schizophrenia.
That is a right path because that is where negative symptoms have been owned for so long, and we already have one very positive study and one near-positive study. When you remove some patients from sites, it was positive. Even in that study, the functionality was significantly better than from placebo. That is really very promising for the next study that we will see again, 12-week data showing significant improvement of negative symptoms without needing the dampening on the brain of the dopamine-blocking medication.
That is unique. No other company has really tried that, and it is bold, but I think it is possible when you do use this precision psychiatry approach, giving the right treatment to the right patients. Now, what other patients might be right patients? Schizophrenia and schizoaffective disorder, for the right, are very, very closely related.
They are almost siblings because you still have all of the schizophrenia side, but there are symptoms of mania or depression. These patients also frequently have negative symptoms. On the left-hand side, major depressive disorder, I think, is a number one target because we have patients where the depression is treated, they are not sad anymore, but there is residual anhedonia, apathy, and also the lack of ability to enjoy themselves and connect back with life.
They are sitting, and they are not sad anymore, but they are blank, and there is a lot of emptiness. Hopefully, for these residual symptom patients in a very frequent disorder like MDD, roluperidone could play a major role. We are all aging, I have to break the news to you, but also the population is aging, and we will have more and more Alzheimer disease patients. You know that.
And we also have two types of Alzheimer's that is really problematic for families and societies. One is obviously where there's the too muchness of psychosis and agitation, and some companies are going that route. But what we're really not focusing enough on is the apathetic subtype of Alzheimer's disease, where basically patients are disappearing from their families. They're just sitting there, and they're not interacting, and that is so painful that you're losing your loved one this way.
You want to reach them, and they're like behind a milk glass. This apathetic type of Alzheimer's disease has a very high likelihood to also respond to roluperidone. Now, looking at Parkinson's disease, where there is a lack of juice in the brain, there's too little dopamine, there's also a lot of depression, but apathy. So here, I think it's a high likelihood that this could be treated.
Similarly, in another neurological disease, multiple sclerosis, where there is a shutting down of certain neurocircuits that need to be lit up again in order to make patients more interact and enjoy their life. COVID has brought us a lot of patients who have long COVID now that somehow can't get back into life, can't light the bulb again in their life, and they are often just sitting around, lying around, and have checked out. So this long COVID post-viral syndrome that we don't fully understand yet what happens in the brain may also respond to roluperidone. And very much related to that is the myalgic encephalomyelitis or chronic fatigue syndrome, which has been around for many, many years, where we don't have anything approved to treat this kind of illness.
And then finally, traumatic brain injury is another disruption of the brain that hopefully a treatment like roluperidone that treats apathy and anhedonia and avolition in people with schizophrenia, where the hardware is impaired. Here, we have hardware impairment after a traumatic event, and it's also a real target. And then finally, let's finish up again with neurodevelopment. What about autism spectrum disorders, where we have also, like with Alzheimer's, a too muchness of aggression and agitation, but we also have this lack of social interaction, where we have this checking out and just being in your own world. You may know that Bleuler, who coined the term schizophrenia, actually felt that one of the main features was autism for people with schizophrenia, meaning being in their own world, being shut off from others. So here, I think roluperidone, again, would have a path forward.
And since there needs to be a pediatric plan, that would be something, I think, to actually study, rather than schizophrenia, which is much rarer in children and adolescents. And other companies have done that they actually use this for agitation and aggression as their primary autism, as their primary target for fulfilling the pediatric plan. So I thank you for the opportunity to talk about this transdiagnostic opportunity for roluperidone once it's, and if it's approved for schizophrenia and negative symptoms. Thank you very much.
Thank you, Christoph. Incredible presentation. Thank you. And I think, very importantly, you see how important it is to bring roluperidone to patients, and afterwards, it might open to a lot of other disorders where there is a huge unmet medical need. So I think it is our duty here to come to this. So let me just go back to the numbers, because everybody likes numbers. This is just to give you a flavor about what is the opportunity when we will have the data in hand of the C19 study. This is really focusing on the patient population we are currently targeting, and these are some data. You know that the prevalence of schizophrenia is, depending on the studies, 1%, 1.2%. so this represents, and here I am focusing on the U.S. only, it is around 3.4 million in the U.S. who are definitely suffering from schizophrenia.
Interestingly enough, the number of patients who are treated or seen by the medical system are not from all the patients, but it is nevertheless 2.2 million people who are seen by the medical system in the U.S. So, a very large population. Afterwards, when you apply our criteria somehow, so patients who have negative symptoms, this is going down to 60% of this population or these patients who are seen by the medical system, and so you end up with 1.3 million people.
And when you are going with patients who are stable, because this is what we are aiming for here, what our studies are recruiting, you end up with around 900,000 patients who might benefit from roluperidone in the U.S. only. Maybe people who have seen our previous data say, "Ah, they have increased the number." No, we have not increased the number.
What has changed since the last review we did is that the number of patients seen by the medical system has increased. In our last analysis, it was half of the patients. Here, it is more than half of the patients, which is explaining the difference here. It is just to be clear that we are not emphasizing or inflating the numbers. It is just because more patients are seen by the medical system. The same is true for the, how to say, the overall market for schizophrenia. It has also increased. It is now at around $7 billion. On negative symptoms, there is definitely no dollars coming because there is no approved drug for the moment.
And when you apply this to our patient population by using the criteria I was showing you before, this is an opportunity for the first indication, which are negative symptoms in patients with schizophrenia. You are speaking about an opportunity of more than $2 billion. Before opening to Q&A, hopefully you have a lot of questions, because I think what we are doing here is so exciting, and when I hear my colleagues speaking about it, how important it is, it gives, I think, to the complete Minerva team the energy to move forward and to continue to work. I think Minerva is the right conference here, because we have definitely here the right pharmacology and the right mechanism of action. It is, I think, the only drug today who shows really clinically relevant improvements.
We are really showing that we are able to improve primary negative symptoms, and after presentations like the one from Christoph, I think you are all convinced that there is a label expansion which is possible with this drug. Importantly, we discussed this, and I think we have what I think we brought to the table, even broader than Minerva, to the medical and scientific community, is to think about the fact that patients with a diagnosis of schizophrenia are heterogeneous. I think we are able to really come up with a clinically relevant population who has really these impairing negative symptoms and with a low risk of relapse. I think this is coming to the notion of precision medicine, but this is extremely important, and I think this is not important only for schizophrenia. We can speak about depression, it is exactly the same, or other disorders.
But I think this is a second pillar of what we are doing here. Now we are understanding more and more data, more and more the patient, and more and more why these patients are different in terms of reacting to the drug, in terms of negative symptoms, but also why they are not relapsing. Something very important, obviously, we need to have a positive C19 study. The team is completely focused on this, but I think it is about execution. It is not about the fact do you have a drug or not. Because when you are looking to the two previous studies, we definitely show a very good discrimination between placebo and treatment for negative symptoms and functioning. It took us time. I know that some of you were questioning me often, "Why did you not start your study immediately after the feedback from the FDA?" I think it was necessary that we open the dialogues, that we had these interactions. As I said at the beginning, we really got very, very good advice in order to come up with the C19 study.
And we learned all from the two previous studies that we have implemented, and it is long to go through it, all implemented in order to really magnify the effect of roluperidone, keeping the placebo effect under control and definitely coming up with a positive study. It is also the right moment because I think the space is really moving. Patients are more aware about negative symptoms. The scientific community is working on it. The medical community is working on it.
It is important, and I wanted to highlight this very strongly. I mean, we are backed by world-class investors, which is, as you know, without having these people supporting us, nothing is possible, unfortunately, in drug development. So thank you to all the investors who are supporting us. I think when you think about the opportunity, there is an opportunity to have a big readout coming during the course of next year, hopefully confirming that the drug is working on negative symptoms and transforming into functional improvement. It is time to hand over to Q&A. So maybe Christoph and Greg and Frank, maybe you can sit. We have Brian somewhere, so can we see Brian?
I can see you. We're good.
Okay.
2. Question Answer
This is John here for Andrew Tsai from Jefferies. As we think about the real-world use case for roluperidone, I can imagine physicians would be incentivized to take patients off of antipsychotics, which come with a lot of safety liabilities. Then I can also imagine there's hesitancy to take patients that are well-controlled on their positive symptoms as well. As we think about discontinuing an antipsychotic and then cross-titrating or even using adjunctively, where do you think the ultimate real-world use case will kind of skew towards?
Maybe we can start with Brian. Brian?
I suspect that both will happen. Some people will start monotherapy, some people will continue an antipsychotic. I think the company would then have the option of providing some education for those people. If a lot of people continue an antipsychotic, might be able to present them with a way, an educational effort that perhaps includes talking about tapering off the antipsychotic slowly. I think Christoph had some thoughts about that yesterday he might want to add.
Yes, Christoph, please.
Yes, I do believe that clinicians will be wary of the worsening positive symptoms, so there will be first an adjunctive treatment. And then since patients always ask us to lower the dose or stop their treatment over months, I think then very slowly go down so that we could catch them should these patients not be guarded or protected against relapse and wouldn't have a bad outcome. But I also, and many patients, I think, will continue this and finish the cross-titration. I think that there are two other groups that we haven't really focused on where this will be used the most and fastest. About 50% of patients are non-adherent themselves, and there are those that are not on an antipsychotic anymore, but they still have negative symptoms.
That's where families might bring them in, where patients are still in contact, and they could be started safely, and maybe the relapse prevention with roluperidone's effect could then be stronger. I think also first episode patients. First episode patients that get schizophrenia treatments, the clinicians are often very unclear, will they have a second relapse or not? Negative symptoms are very common, and patients' families want us to try at least once without. And that's the perfect population where we, at the moment, have nothing to offer. We say, "I think 80% chance that you will have a relapse, so we need to continue." But what if I'm in the 20%? So those patients that are often even based on guidelines given at least one chance, that's the perfect treatment for roluperidone.
Yes, and Frank.
Let me say this, and by the way, I'm Frank Sasinowski, the guy Remy kept referring to as Frank.
Sorry.
No, no. I left the FDA 39 years ago as Deputy Director of Health Policy, Commissioner's Office. 39 years, I was with one law firm helping people get new drugs through the FDA pre-approval call. I have helped over 200 new chemical entities get approved, including REXULTI, COBENFY, and CAPLYTA in the world of schizophrenia. Let me say this, that FDA, I am all about FDA. You have been hearing about science, now a little bit about marketing. I have a myopia. I only think about FDA. That is all I think about. With respect to FDA and getting to market, the FDA cares about making sure that it has the right evidence for which it can label so that doctors have adequate directions for use.
Beyond that, so that they will approve it, the FDA, if the Phase A results come in next year and they are positive, the drug will get approved. It will be approved because it is effective. The questions about relapse are a safety question. Safety questions are, the FDA has a lot of tools in its toolkit to deal with safety issues, including labeling. The relapse issue, it is not a big issue. In fact, at our September meeting with the FDA, the FDA said, "Yes, we agree with you, Remy. We agree with Minerva. Your relapse rate is likely lower than it is in general because of the patients that you are going after." What I want to get to is your question about label. The FDA only cares about labeling it on the evidence that it is provided with.
It would be provided just for the patients that were studied in C03, C07, C19. The rest of it, which you are talking about, like Christoph is talking about, first episode and these other things, and what you were talking about. That, the FDA says, is not on our shoulders. It is not in our task. We are not responsible for the practice of medicine. What people do off-label is up to the medical community. We only are empiricists. We just deal with data. I just want to make sure that you understand there is a difference between what the FDA will approve you for, which I think will happen if the Phase III results, 12-week results, are positive.
In fact, in our discussions with the FDA, what is fascinating to me is that in this discussion today, as a regulator, there was no discussion about whether or not this drug works. There was no discussion of that in September with the FDA. The CRL, the complete response letter, which we got in February 2024, which says, "We are not approving you on the basis of C03 and C07," the first issue was substantial evidence of effectiveness. The most important issue to the FDA was, does it really work? Does it provide benefit? Yet, where are we today? Nobody is even talking about it, not even the FDA much, when we met with them in September.
Which means that, to me, as a guy who knows nothing but FDA, this drug is getting approved. Those Phase III results at 12 week come in, and FDA almost has no doubt that they are going to come in positive.
Yes, but I think it is very important to make these distinctions. Really, thank you, Frank. By the way, the FDA does not call me Remy. I am not yet at this stage. But a small thing I would like to add. We already have a lot of data because obviously we are very well aware that, I mean, this drug might be administered on top of something else, antipsychotic, but it can be also on top of another treatment, as you have heard. I mean, this will be also maybe prescribed beyond the schizophrenia.
So, we have already a study we have performed, which is called the C18 study, where we have co-administered olanzapine with our drug, just to demonstrate that, I mean, it is possible. I am not speaking about the efficacy, just that it is safe.
I think it is a small study we have done, but definitely it is safe. We have a lot of preclinical data showing that the risk of DDI is extremely limited with our drug. But again, this will be taken care of during the labeling. What I wanted also to mention, because, I mean, this was often a comment I received from a lot of people, "Why are you not doing like everybody, put this on top of an antipsychotic?" So we decided, and I was stubborn, and I got a lot of criticism. I said, "No, let us first focus on this patient population we have discussed today to demonstrate that we are improving the primary negative symptoms, and afterwards we move to something else." But think one second about developing it on top of an antipsychotic. Which dose should we use of the antipsychotic.
What is the level of binding of dopamine in the brain we should have in order to co-administer the drug? I think this is something which is a little bit more sophisticated than just to say, "Put it on top of an antipsychotic and hope for the best." Just to mention that we are thinking about it, we are conscious about it, and we're working on it.
Let me say this about that. Slide 11 that you saw in this slide deck quoted Stephen Marder at UCLA for saying that a monotherapy is the best design to look at a treatment for primary negative symptoms. Okay? Stephen Marder at UCLA was the person for whom Mike Davis, who is currently the head of the Center for Drugs at the FDA, Mike Davis worked under Stephen Marder at UCLA. So and Mike Davis then is a psychiatrist who's keenly interested in schizophrenia, studied under Stephen Marder. When Mike Davis left the FDA temporarily, he was at the FDA, he left for a little while to go to a nonprofit called Usona to help work on psychedelics for treating PTSD. When he left, he called me, he said, "Frank, the best work I saw at FDA when I was at FDA was from you.
I'm now the CMO at Usona. Would you represent me?" I said, "Sure, Mike. I'll do that." Mike now is back at the FDA, a psychiatrist, head of the [ Center for Drugs ], whose profession was built on looking at schizophrenia, and with people like Stephen Marder who focus on negative symptoms. Guess what happens when you have somebody like me who knows people like that, who are interested in this issue? It means that we have an ability to invoke, escalate these kind of reviews, so that if we have any hiccup in our review when these Phase A results come in, we have many ways in to talk to people who can help with the decisions to be made.
Next question, because I think if we take as long for each question, I think we will be here until 2:00. Next question, please. Mikhail.
Do we have any from the audience?
Let's go through the room and after.
Sure. Mikhail Keyserman, LifeSci Capital. Maybe two questions. One is, when you look at this patient population and think about quality of life, obviously PSP is measuring a lot of that function on a daily basis, but how are you guys thinking of capturing the quality of life benefit that roluperidone really offers for these patients? That will be obviously very important for the pharmacoeconomic argument as you guys are going to go to payers and really think through that. I would love to get some more thoughts around that.
Who would like to take this question?
I can. So basically, there is no dedicated quality of life scale in this study at the moment because the more rarefied the assessments, the more likely you will beat placebo. But we have clear data that functioning improvement really translates into quality of life. So there could be triangulation studies looking at other studies where when PSP improves and it did have a quality of life measure, that that also improved. So I think that is less in question, and functionality is measurable and observable. So I think that has more traction even with payers than quality of life, which is a very subjective and neither here nor there kind of an outcome. But maybe Greg, what is your opinion?
Yes, I definitely agree. I can also add there are some of the items on some of the scales that are being administered that get at the subjective experience of the patient. So how much, in addition to what they are doing, how much do they want things to change? How important is that? How connected do they feel with other people, not just how much are they actually engaging in those interactions? That subjective portion is very important for quality of life.
Brian, do you want to add something?
Well, you may not like what I want to add. My thought was, how difficult would it be to ask the patients at the end of the study if their quality of life has improved and look at it for placebo versus drug?
You are spot on because we have this kind of question at the end of in our new study. So definitely we have it and we will document it. Hopefully the two things will match together.
For some reason that I do not quite understand, FDA is fascinated with what we call exit interviews in all studies across all disciplines. I say I am perplexed by it because the FDA really does dig into those exit interviews, the very thing that Brian was asking.
The very thing that is being done in Study 19. The FDA, the Associate Director of the Office of Neuroscience, Dr. Michelle Campbell, is a pharmacometrician, and she likes to look to see the correlation between what those exit interviews say about how people are changing their activities of daily life and look at their scores on instruments like PSP or the PANSS, or the NSFS. There is a great regulatory interest in looking at that. It is a very good question. I do not know if you knew how relevant your question was, but it was a great question.
Michael is an open book, so probably knew it. Any other question, please? If not, is there a question from Doug.
Doug Tsao from H.C. Wainwright. I am just curious how, given the introduction of new mechanisms of late, as well as over the years there have been some drugs that have tried to make claims around treating negative symptoms, although have never been able to get labeling. I am just curious from your perspective, like a product like VRAYLAR, how effective they are, and even some of the newer agents that have been approved, how has that affected the pervasiveness of negative symptoms or their severity, if you will, and the need for both primary as well as secondary negative symptoms?
Do you want to go first?
Go first.
I was going to say, I think it's becoming clear that drugs that have shown an improvement on negative symptoms measured very broadly, they also concurrently are having improvements in these other domains, positive, depression, anxiety, disorganization, et cetera. The real question is there a temporal effect? Are those improvements lagged in producing the improvements in negative symptoms? I am not aware of companies doing those specific analyses. That is one way to test it.
But the assumption is, because they are occurring concurrently, that there are secondary effects occurring, and I think it is a very logical assumption. So to date, no drug has really been thought to cross that threshold. That has been an actual change in primary negative symptoms. The other issue is the enrollment criteria. Most studies have had a very broad enrollment criteria. They have not enriched for the primary phenotype as Minerva has.
That over-inclusion results in a high amount of these secondary phenotype patients who are driving the improvement in negative symptoms due to the secondary source improvements in positives of depression, anxiety.
No, I think you're, and Greg, you're addressing a very important point because if you take the example of VRAYLAR, when you're comparing VRAYLAR to risperidone, obviously you will win because risperidone is known to be very sedative, to have a lot of side effects. I think the study design and the patient population is important. Just speaking about depression, so we have capped in our study the level of depression. This is very important because I always remember first time Brian came, he said, "I don't believe your data because you have probably not controlled for mood." Indeed, we controlled for mood. Here we have Brian still supporting us. I think all these kind of things are very important.
They are not seen when you're looking to a study design, but this is exactly what we are implementing in our study in order to really being able to claim that there is an effect on primary negative symptoms. We have even taken a patent on mood. I think the drug is doing something on mood, but, I mean, to really demonstrate what we wanted to demonstrate, you have to come up with this kind of criteria. I agree, often it is much too large, and to claim that, I mean, you have an improvement is a little bit a conclusion which is taken too rapidly, basically.
You also mentioned how the landscape might change with some of the agents that are coming. Most likely, implicitly, you talked about the muscarinic modulators. The muscarinic agents have, especially M1 and four, some reason to believe that they may help cognition, but there are not good data at the moment at all that independent of improvement of positive symptoms, they can improve negative symptoms.
The partial agonists you mentioned, that's aripiprazole, but also aripiprazole, brexpiprazole, they lack some of the secondary negative symptoms due to over-sedation and D2 blockade, but we don't have a solution for these residual true primary negative symptoms, so they are still out in the open. I don't think that any agent at the moment in the making really has a very strong prospect, except maybe for LB 102, but there is no study ongoing at the moment, which is an N-methylated amisulpride.
That will be a small subgroup of patients, whereas the muscarinics, I don't think they are used mostly in combination, and with the combination, it's hard to break through any of the D2 blockade. I think roluperidone at the moment would be the sole potential option that I see that's viable.
Frank?
What I was going to say is that if you went back to that February 2024 complete response letter, the FDA said no when we first tried to get marketing approval, you will see that one of their comments, I think it was the third comment down, it talked about how difficult it is if you had a drug on top of an antipsychotic. Because the antipsychotic, as Greg explained, the antipsychotic can either induce secondary negative symptoms or can treat secondary negative symptoms. If you are just looking broadly at negative symptoms, like I helped in the approval of COBENFY, and I know when they came out with their analysis, they said, "We treat secondary, and we treat negative symptoms," because if you looked at the PANSS, you looked at the negative symptom domains, you would see they had an improvement.
As Greg was explaining, and as FDA said in our complete response letter, you cannot tell where that is coming from. I think that you need, it is just like Stephen Marder on Slide 11 said, and that is why ISCTM has endorsed this idea that if you are going to look at primary negative symptoms, you have to look at a monotherapy study design.
Any other question before maybe questions coming from people who are connected to?
We have several questions that have come in through the webcast in written form, a lot of which are a good continuation of what we've just been discussing here. This one's directed to Dr. Kirkpatrick. If a treatment for negative symptoms, like roluperidone, has more of an effect on function than the treatments for the positive symptoms, wouldn't you expect it to have a stronger effect size on the PSP scale than, say, the antipsychotics in the populations that they've studied?
Well, just not necessarily. Keep in mind the comments I was making about the history of these patients. They have a long history of not being successful in a number of areas as a group, and overcoming that, partly through encouragement and better experience and treatment, it would be really important. Antipsychotics work relatively quickly. Recovering from a lifetime of habits would, I think, reasonably take longer. What's interesting is that in 12 weeks, you could see a significant effect on PSP at all.
Just one more point. The effect size for PSP with the antipsychotics used in the acute studies are again suffering from the pseudo-specificity, because your functioning goes up when you're not withdrawn and anxious that people might hurt you. So you can't compare that effect size versus the residual negative symptoms that you're describing.
We have another question that's directed specifically to Dr. Correll. Your comments about the possible effect in early prodromal symptoms was interesting, and were you trying to imply that it could alter the future disease progression? Secondarily, it asks, among the nine indications that you showed on Slide 50, you said MDD would be your #1 choice, but would you envision this being used as monotherapy, adjunctive therapy, or in the treatment-resistant depression setting? How best to show the effect in a clinical trial setting in MDD?
Yes. I mentioned with the clinical high-risk syndrome that this is really something to try to figure out. These patients are not so easy to identify while they're on the path to maybe psychosis or other disorders. It is a testable hypothesis whether intervening with the mechanisms that underlie negative symptoms, one could stop the progression into other illnesses. I think we do not know enough about it, but that could be a Phase IV question. It would not be my first question, but it is certainly something very intriguing. Now, for the antidepressant side, there we do not have dopamine blockade that could counter some of the roluperidone effects.
I think here, one could try the combination treatment in patients who have needed antidepressants in the past and have residual symptoms, but there are others that might have residual symptoms even though they are coming off the antidepressant and have still some cognition, insomnia, and negative anhedonia type of symptoms. That would be a separate group that one could try as monotherapy.
I can add a comment too about the clinical high-risk group. One of the really important things to know is that population, it is very prevalent for them to have negative symptoms, over three-quarters. I think the published numbers are 82% will have negative symptoms in the clinical range. Importantly, these are not attenuated. They are not attenuated like their positive symptoms are. Their negative symptoms are as severe as people with schizophrenia. That is point number one.
Point number two is when they occur, even if they do not convert, meaning even if these at-risk youth never develop full psychotic disorder, they continue to have poor functioning. Whether their positive symptoms improve, whether they develop depression, anxiety, et cetera, they continue to have poor functioning. This drug could be very helpful for many people in this clinical high-risk syndrome group. Treating their negative symptoms is going to improve functioning.
These kids need clinical attention and help regardless of whether they convert. They are a clinical target that should be tackled.
If you are a teenager, it is better if you are having some social success and learning how to maneuver in the adult world than not. So if you give them some success by helping them with the negative symptoms, that can only help them in later life.
I agree. We probably have time for one more question that came in, unless there is any more in the room, or ask this one. This is directed for all 3 of the speakers, and it is asking, in everyday clinical practice, and how good are clinicians in their initial diagnosis and workup in identifying the same kind of symptoms that are specific in this clinical trial for roluperidone? Or is it going to involve a lot more education so that they can diagnose the patients that are most likely to benefit from this? Whichever one of the 3 of you.
They routinely assess positive symptoms and negative symptoms. The finer points of negative symptoms, I think, are usually not well taught, and they are going to be a little fuzzier on that. But I think it is one of these things where they say, "Well, I cannot define it, but I know it when I see it." It would be helpful to help them. It would be helpful if we could teach more people to some of the finer points in the assessment of negative symptoms. On the other hand, I think that actually the drug itself will end up teaching them a great deal.
Greg? Christoph?
Yes, I definitely agree with that. I think clinicians are almost always very adept at assessing depression, anxiety, disorganization, understanding when there are antipsychotic-induced effects. They're implicitly aware of these factors that are common secondary sources. Whether they label them that or not may not matter that much. I think that they'll be very good at knowing when they're present, and by default, knowing when they're absent as well, which will define the treatment group. I think in routine clinical practice, they are very adept at making this determination. It's just really formalizing.
Yes, I agree that clinicians know about positive and negative symptoms, so that's the basic teaching. But it's more like a qualitative, dimensional way. It will be very helpful for Minerva to develop some tools that accompany that in order to make people much more focused on it, because you watch for what you know, and you recognize what you can measure. It has to be very simple, just absent, mild, or more than that. But that's doable, and we've had also examples for that, like quetiapine going into many billions of dollars for bipolar depression when there was a tear-off sheet and patients filled out something, how they felt and what symptoms they had. Having tools available sharpens the eye and brings out that there is a new treatment for a condition that we currently couldn't treat. Education will be crucial for that.
Yes. Well, one thing I want to say on that from a regulatory perspective, and that's all I can bring, what strikes me is that if the question was saying, can people trained in the field identify these patients that are the patient population, an indicator to me, as a kind of a regulatory maven, an indicator to me is that the speed with which C03, C07, and C19 enrolled, if you needed to go out and have a whole campaign to teach physicians how to identify these patients, then it would have taken longer than a normal antipsychotic study in schizophrenia to enroll. The pace at which these studies enrolled was the same. It's as though physicians understood.
It's like Brian said, it's like Justice, as the lawyer in the room, Justice Potter Stewart said about pornography, "I know it when I see it." Brian didn't quote the good justice, but that's what he said, "You know it when you see it.
Yes. No, it is definitely a paradigm shift, and it needs definitely some help to educate a patient, caregiver, and also to help the prescriber. It is completely right. I think, Christoph, we have to think about these kind of tools, because they are simple. The beauty here is that we are not speaking about a fancy biomarker. We are not speaking about I spend my complete life on biomarkers, but definitely, this is very simple to identify these patients and to make sure that it means they are the right patients for our drugs, which is not always the case, to be very honest, in medicine.
All right.
Any other questions?
I think we have exhausted the questions. If you want to turn it back to Remy to close things up.
Yes. I hope it was helpful. I hope you enjoyed it. I enjoyed it much, because it shows what we are doing is important for patients, and this is exactly what is motivating us. We will continue. We promise that we will continue to do all what we can in order to get to successful C19 study. Things are ongoing, are going well. We are really recruiting. We are still on time for the readout of second half of next year. Obviously, when we are coming closer, we will be more precise. Today, I keep this as generic as possible, because we need to work, focus, and come up with good data for the best of patients in need. Thank you again, and I think we have some snacks or something to eat.
You are more than welcome to stay, to speak with everybody, Minerva colleagues, our KOLs. Thank you again, Christoph, Greg, and Brian, and my friend Frank. Really, thank you for this.
Thanks for coming.
Transkripte auf Deutsch freischalten
- Alle Event Transkripte auf Deutsch
- Sofortige Übersetzung
- KI-Zusammenfassungen für die wichtigsten Insights
Minerva Neurosciences Inc — Special Call - Minerva Neurosciences, Inc.
1. Management Discussion
Good morning, and welcome to the Minerva Neurosciences Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Minerva website following the conclusion of the event.
I'd now like to turn the call over to your host, Remy Luthringer, Executive Chairman and Chief Executive Officer at Minerva Neurosciences. Please go ahead, Remy.
Thank you so much. Good morning, everybody. It's a real great pleasure to give you an update on Minerva progress in bringing roluperidone to patients afflicted by schizophrenia and suffering from negative symptoms. And we all know that negative symptoms is the type of symptoms, which is keeping these patients out of any decent life. And it is true that over several decades of research and failed clinical trials, we have not obtained a drug which is helping these patients.
I think today, this unmet medical need becomes a reality. And I think we are at the stage where roluperidone is probably the first treatment for negative symptoms in patients suffering from schizophrenia.
Next slide. So this is just a disclosure. I will not insist on this one. So I'm very, very honored and very pleased to have with me today Professor Gregory Strauss and Professor Brian Kirkpatrick. It would be difficult to give their complete CV, but what I can say just simply is that, I think Greg and Brian have contributed enormously to advance the understanding of negative symptoms of patients suffering from negative symptoms. And they really are contributing immensely to advance the field and hopefully help us to bring the first drug for negative symptoms to patients. So maybe when Greg will speak or Brian will speak, they can give a little bit more details about their CV. But again, thank you, Greg, and Brian to be with us today.
So what we will try to address today are a few points. And Greg will start first, and he will really define what are negative symptoms because I think it is important that we have really a redefinition of negative symptoms, and Greg will do this, I know very well. But I think what is also very important, what Greg will address is the impact of negative symptoms for patients and for their families because, again, negative symptoms are the type of symptoms which keep these patients out of any decent life, any job.
Afterwards, Brian will address the challenges, but I think also the solutions of assessing negative symptoms in clinical trials, in patients with negative symptoms and suffering from schizophrenia.
And last but not least, I will give you an update of the confirmatory Phase III trial we have discussed a lot over the last few months and years with the FDA. And afterwards, we will open to Q&A.
But before giving over to Greg, I think to develop a new drug, to develop an innovative drug and to really have a paradigm shift in the way you are treating patients, you need to have several items, several aspects which have to come together. And this is what I call the Minerva conferences. And I think we have it as we speak. Why? Because when you're looking to the interactions we had with the FDA and the very constructive and productive meetings we had with the FDA, in order to come up with the potential design of the Phase III, I think this is extremely important.
The FDA even organized a public meeting where they invited KOLs, they invited representatives also of the patients in order to discuss what is the best way to move forward and to develop a drug for negative symptoms. And I can only thank them for all these efforts in order to help us designing the next Phase III trial, the confirmatory trial.
The other aspect, which is important, and we already spoke about it a little bit is to have the scientific medical research community aligned. And I think over the last 2 decades, definitely, we made a lot of progress in the understanding of psychotic disorders of schizophrenia and particularly negative symptoms. So I think this was also important to come to a stage of understanding of the negative symptoms, which contributes to this confluence I am speaking about.
And I have been very long in drug development. And each time I have seen an advance in a space, in an indication, in a therapeutic indication, you always need a pharmacological tool. You need a drug in order to test hypothesis in order to validate some scales. And I think roluperidone is really filling this gap because we have already clinical data. And definitely, roluperidone is probably the best drug currently in development in order to improve negative symptoms.
And last but not least, because we -- all this needs to be financed, I'm extremely honored and proud that we have the chance to have top-tier investors who have put a significant amount of money in order to help us to go to the next stage of development of roluperidone and hopefully to bring roluperidone to patients. So this is really, I think, a key moment we have here. And this does not happen very often, but here, we have all the alignments necessary in order to move forward.
Now let me just give you some color about the general alignment we obtained with the FDA or we discussed with the FDA for the Phase III trial we are planning to start very soon. And obviously, we'll give you details about timelines at the end of this presentation. But the first thing, I think where we were able to get alignment with the FDA is that schizophrenia is a heterogeneous disease and each patient is quite different. But nevertheless, when you go to the groups of patients, I think we aligned with the FDA about the fact that there are patients out there who have really high negative symptoms and have a low risk of relapse of positive symptoms. So this was obviously a very important step in order to continue with the discussion about the study design.
The second aspect, which is a very, very important aspect is that we also got alignment with the FDA about how to design the study. And here, as you can see, we are aligned about using the monotherapy approach. So we are not putting this on top of antipsychotics like most of the studies have been done in the past, but we are going with monotherapy, and we are comparing in monotherapy roluperidone versus placebo because, as you know, there is no approved drug for negative symptoms. So this is also very important because this allows to really tell based on the data if we have a direct effect on the primary -- on the disease-related negative symptoms. So this, again, sorry to insist, but this is a very big achievement.
So we also agreed about the duration of the study, and we have agreed also about what is the primary endpoint; and the primary endpoint, as you can see here, will be measured at week 12 like in the 2 previous studies we have carried out and having this alignment is also very important because we have already previous knowledge about the duration of the treatment and the primary endpoint.
And again, what the FDA asked us to do, and I think this is completely important because in the 2 previous studies, we had extremely low relapse rates of positive symptoms. So what the FDA asked us to do is to do a comparison between roluperidone and standard of care, which are antipsychotics in order to monitor the number of relapses in the 2 conditions, roluperidone versus standard of care. And I think it is really fair to say that all this represents a new treatment paradigm, and this is what we are working on and trying to execute.
Now Brian -- sorry, Greg, let me hand over to you. Yes, please.
All right. Thank you very much, Remy. I appreciate the introduction, and I'm very honored to be here to speak to you today about negative symptoms and how they impact people with schizophrenia and their families.
So I am a Professor of Psychology and Neuroscience at the University of Georgia, and my research primarily has focused on negative symptoms in the schizophrenia spectrum, not just on adults with schizophrenia, but also at youth who are at clinical high risk for developing psychosis who have prodromal syndromes. And much of my work is really focused on identifying the mechanisms of negative symptoms in particular.
Now we know that schizophrenia is experienced worldwide. It's diagnosis that affects about 83 million people worldwide, including about 3.4 million in the United States alone. And it has an incredibly high financial burden. We know that estimates are about in the billions, about $34 billion alone for the effect of schizophrenia financially in the United States annually. And it is, in fact, a leading medical cause of functional disability. So even compared to other diagnoses like Alzheimer's, dementia, even things like spinal cord injury, which you would associate with very high rates of functional disability, schizophrenia annually is one of the leading causes, if not the leading cause each year.
It also, of course, has a severe impact on social, occupational, functioning and independent living. Many people with schizophrenia experience difficulty forming relationships, whether that be friendships, romantic relationships, relationships with family members, et cetera, also maintaining a gainful employment, finishing school and basic independent living activities. And we know that negative symptoms are the strongest predictor of poor functioning and a strong predictor of functional disability itself.
And if you look at the figure here on the screen, one of the things that you can see is positive symptoms highlighted here in the green line emerge in this prodromal or pre-illness period. So they emerge in an attenuated form before the illness even onsets. And then once the person hits their initial episode, they typically experience a very rapid increase. And then the symptoms will fluctuate throughout the course of their illness. And indeed, in fact, get better much of the time later in the course of illness. With treatment, this rate of change will typically improve for positive symptoms. Many people with schizophrenia, their positive symptoms will respond to antipsychotic treatment.
Interestingly, negative symptoms emerge often years before the onset of these attenuated positive symptoms. So years before these subtle hallucinations and delusions develop that later become full-blown, people will have early negative symptoms, reductions in emotion, motivation, social activity, emotional expression and speech that occur here often up to 5 years before these attenuated positive symptoms, reflecting perhaps the earliest window we have into risk for the later development of schizophrenia.
Now importantly, once they do develop, negative symptoms typically persist. So they actually become severe, clinically severe before the onset of schizophrenia itself and then typically plateau after illness onset. And on their own without treatment experience little to no improvement, they remain stable over time. And when treated with antipsychotics are minimally responsive.
So we know that negative symptoms are a critical treatment target. They're associated with poor functioning, poor quality of life, et cetera, and markedly associated with disability, much more so than positive symptoms, which are the key focus of antipsychotic treatments. And there's general consensus in the field that schizophrenia has a profound impact on patients' lives in these ways, but also the lives of their relatives, their caregivers in terms of impacting their quality of life and impacting the quality of lives of the patients themselves.
Unfortunately, despite this clinical importance, we are really experiencing severe challenges in treating negative symptoms of schizophrenia. We know that current pharmacological treatments have been minimally responsive. Current psychosocial treatments, meaning talk therapies like cognitive behavioral therapy, social skills training, they're also minimally responsive to those types of treatments. So there is a really big landscape for treating negative symptoms, and there's a huge treatment need that remains unmet in the field of schizophrenia.
We know that the antipsychotic treatments may even worsen negative symptoms in some of the patients. They can, for example, induce sedation, they can induce what we call anhedonia, reductions in the experience of pleasure and actually worsen these negative symptoms for some people.
Clinical practice and drug development have really focused on treating the positive symptoms, leaving negative symptoms as a key unmet need in the treatment of schizophrenia. And since there is no FDA-approved therapy for the treatment of negative symptoms in schizophrenia, this is really an urgent need for the field and something that the patients themselves are critically interested in.
Now when we talk about negative symptoms, I want you to know that currently in the Diagnostic and Statistical Manual for Mental Disorders, the DSM-5, there are 2 broad dimensions that are described. And these are really organized hierarchically, meaning that there are 2 higher order dimensions that we call experiential and expressive. And beneath those 2 higher-order dimensions are 5 lower-level domains of avolition, asociality, anhedonia, blunted affect and alogia. And these are thought to represent independent constructs that can reflect different treatment targets.
Now I want to tell you a little bit about each of these, so you have a sense of what the 5 negative symptom domains are.
The first is Avolition, which you can think of as a two-pronged abnormality. One is in an experiential component of having a subjective lack of motivation. So a lack of desire for engaging in goal-directed activities, for example. But also that had -- manifests in a behavioral component as indicated by a reduction in engaging in goal-directed activities, reductions in engaging in work or school activities and also poor self-care. So these are often folks who do not desire to engage in goal-directed behavior and they don't do so.
Asociality, the second domain, of course, revolves around social interest and activity. This is a reduction in the interest in and engagement in social relationships of all kinds. These can be friendships, romantic relationships, family relationships across all the different types of social interactions we might have. These folks will have reductions in how often they interact with others and the size of their social networks. And critically, they're not interested in developing those relationships. They're not important to them. They don't think about them often.
Now Anhedonia, the third domain, is classically referred to as a reduction in the ability to experience pleasure. So things that would have typically been experienced as pleasurable by most people would not necessarily bring these people fully intensely pleasurable experiences. We now know that it's not just restricted to that ability to experience pleasure in the moment, however, but also to anticipate future pleasure. And that's really critical for finding the motivation to engage in future pleasurable activities, right, for getting people up off the couch to actually engage in a recreational activity that can bring them pleasure, they need to anticipate future pleasure by generating simulations of pleasure mentally that can produce enough pop in that moment to get them to then act on it.
And of course, anhedonia also is associated with the behavioral component of a reduction in the frequency of pleasurable or recreational activities. So each of these 3 domains within the experiential dimension, they all have in common that they have this subjective internal experience component, but also this diminished behavioral component where they don't engage in goal-directed social or recreational activities.
Now the second dimension, the expressive dimension includes the 2 domains of blunted affect and alogia. And Blunted Affect refers to reductions in emotional expression in the face and the voice and in body gestures. So these are people who we refer to, for example, as having flat affect. They have a monotone voice. They have a wooden emotionless expression, for example.
Alogia is basically going to consist of a reduction in the quantity of speech. So these people, when you ask them a question, will respond with bare minimal response. It may be a 1- or 2-word answer. And the person who might be speaking to them may feel that they really have to pull to get more detail, to get more information out of the person because they don't spontaneously elaborate. They're providing just enough information to answer the question and sometimes not even that.
So importantly, these 5 domains are minimally responsive to antipsychotic treatment, and they reflect a critical treatment need. And even though we talk about them as being 5 independent constructs, we think that they may not, in fact, all be created equal, if you will. We know that the domain of avolition, which again is a reduction in motivation and goal-directed activity is more central than the others.
And we've learned this through a number of different types of mathematical approaches such as network analysis, for example, where we've mathematically tried to deconstruct which of the domains carries the effect on the other, meaning that even though they're independent, these domains can interact with each other. They can have causal influences on each other.
A good analogy for this is imagine that the symptoms, the 5 domains are airports and one of them could be the major hub. I'm in Georgia, so I'm going to say Atlanta. Imagine Atlanta is a major hub. And to get to all of the other locations, one would have to go through that major hub, go through Atlanta to get to these other cities. We think that avolition has this role in negative symptoms. In other words, why does someone not engage in social activity, recreational activity? Why don't they show emotion on the face or in the voice or talk much? It's because of deficits in motivation.
The deficits in motivation are so central that they underlie and even have causal effects on the other domains. So when someone has deficits and motivation, these other domains are more likely to emerge. And we think that avolition is driven by specific neurobiological mechanisms. And these are true across psychiatric diagnoses, not just within schizophrenia or the schizophrenia spectrum, but other diagnoses, such as neurocognitive or neurological disorders, such as Alzheimer's, dementia, Parkinson's, traumatic brain injury.
All of these are conditions that also display negative symptoms that manifest behaviorally and experientially similar to what you see in schizophrenia with similar severity in general. And we know now through different modes of research that use different neuroimaging techniques that cortico-striatal circuitry in the brain is really critical for this symptom of avolition, and this cuts across diagnostic boundaries.
And here in this diagram, you can see that avolition is thought to, in fact, have this causal effect. When it's present, it drives the existence of the other domains, but also poor functioning. So it's driving poor social functioning, poor occupational and school functioning and activities of daily living. It also drives another critical treatment target in schizophrenia, which we refer to as cognitive impairment. So deficits in things like attention, working memory, executive functioning that are also related to poor functional outcomes. Avolition is a key driver of cognitive impairment as well.
Now roluperidone has shown very interesting effects that were replicated in the Phase IIb and III trials. What we did that you can see illustrated on the screen here is we took a network analytic approach to understanding why the drug achieved its effect. So we know that the drug was achieving an effect on the broad constructs of negative symptoms, the broad construct, the 2 dimensions, but we didn't know causally which domain was carrying those effects. And so we tested this hypothesis that you saw on the slide before you that it was avolition or these reductions in motivation that were driving the global treatment effect that roluperidone had. And that's indeed what came out.
If you look at these figures here on the top with the red areas that are circled, what you see is that reductions in the internal experience of avolition, meaning that subjective motivational deficit were what separated out the treatment arm from the placebo arm, meaning that when the drug hit motivation, when it improved motivation, what you saw were these global improvements in the other negative symptom domains.
Now critically, we wanted to see if that same effect could be replicated in the Phase III trial. And here it was. This figure here is showing a direct effect. We were able to isolate using more advanced mathematical network analytic techniques. We were able to isolate the direct effect of the treatment itself and identify which of the negative symptom domains ended up having these causal interactions to lead to these improvements in the other aspects of negative symptoms. And again, it turned out to be avolition. So here across 2 separate clinical trials, we found this replicated effect that avolition was what carried the day is the reason why we saw these global improvements in negative symptoms from roluperidone. And we know that those effects are important to people with the illness and their relatives or caregivers.
This slide presents data from 2 separate studies, and I'll walk you through this. The first study is one that we conducted here in my laboratory at the University of Georgia, and we call this the self-perceptions study, and it was constructed to understand the subjective viewpoints of people with schizophrenia and their relatives or caregivers on why negative symptoms are important to them, on how they define them, what they think caused them and how much improvement they would need to experience for their lives to change. In other words, what magnitude of improvement would they deem clinically meaningful.
And you can see the results here in this table. If you look at the portion on the left, what you can see are the 2 higher order dimensions of motivation and pleasure, that experiential dimension; and the expressive dimension and the individual domains that fall underneath them. And what we did in this study is, we essentially asked patients and separately asked their relatives or caregivers to tell us what magnitude of improvement on a clinical rating scale -- on the brief negative symptom scale would be considered meaningful for them. And we didn't define meaningful for them. We left it open to their own interpretation, and it could have related to social, occupational improvement, improvements in school, quality of life, et cetera. So what -- however they defined meaningful improvement in their lives.
And what we did is we quantified the magnitude of change that would be needed on the brief negative symptom scale, which has a range on the individual items from 0 to 6. And so in this table, what you see is in comparison to ratings given by clinicians, which you can think of as the kind of the landmark for where that patient's negative symptoms were. We looked at how much of a decrease the patient said they would need to achieve for their lives to meaningfully improve.
And the answer here for the motivation and pleasure dimension was about 0.65 points of improvement. For the expression dimension, it was 0.23. So on this 0 to 6 scale, this was the magnitude of improvement that patients deemed would have a meaningful impact on their lives relative to where clinicians rated them in terms of their negative symptoms. The relatives and caregivers also provided these same ratings on the magnitude of improvement that they thought that the patient would need to achieve for their lives to be meaningfully improved. And you can see it's roughly in the same ballpark.
Now critically, what you see here on the right is something that we can use to compare the magnitude of improvement that clinicians say is clinically meaningful with the magnitude of improvement that the patients and their relatives say would need to be achieved for a drug to be meaningfully impactful in their lives.
And so on the right here, what we did is we took data from the roluperidone Phase IIb trial. And we essentially anchored it to the Clinical Global Impression scale. So we looked at the relationship between the Brief Negative Symptom Scale scores and this kind of anchoring method of the Clinical Global Impression score that is related to a minimum clinically-important difference or minimum clinically-important change that the patient identified that would need to be achieved for clinically meaningful improvement to occur on a medical definition, right, so that the treating clinician deemed meaningful.
And so here, again, this value reflects the magnitude of improvement the clinician deemed clinically significant on that 0 to 6 scale on the Brief Negative Symptom Scale to be deemed clinically meaningful. And the clinician here, you can see deemed an improvement of 0.72 points change for the MAP dimension and 0.59 for the Expression dimension. And these numbers are in the same ballpark. They're really pretty comparable to what you see in comparison to what the patient said they would need to achieve for their lives to be meaningfully improved.
And this is something that's really critical for the FDA. This type of data on the magnitude of improvement needed for a patient from their perspective to deem a treatment meaningful has not really been published much in the field. So this is really important for the FDA to make this type of comparison and say that the magnitude of treatment a drug has achieved is not just comparable to what a clinician would say is important, but also to what the patient and their relatives or caregivers would say. And roluperidone does very well here. It's roughly equivalent to and sometimes even better than what the patient would say that they need to improve to show a meaningful change in life.
And with that, I will stop my portion, and I will introduce you Dr. Brian Kirkpatrick from the University of Arkansas.
Thank you, Greg. Good morning, everybody. So I'll be talking about measuring and what to do with measurements of negative symptoms and how that applies to clinical trials. A lot of -- there are a lot of studies that have had industry and academic that have focused on negative symptoms as their primary outcome. And none of them have, recently we've looked at it, there aren't other drugs that has been well validated for effectiveness for negative symptoms specifically. There are several contributions to this. One of them is a high placebo response rate. So this is noise. And there are many things that contribute to this.
One important one is simply that you have a great deal of attention in these clinical trials. You come in and people are smiling at you and very interested in what you say. And that has an impact on people. This is a widespread problem. It's in other areas of psychiatry, not just in schizophrenia. And one that is particularly a problem for people who have schizophrenia in these trials is antipsychotics themselves. They're dopaminergic agents that can inhibit the brain's reward system. And so you can -- your attempted therapy -- the therapy, whatever the other drug is, may have a diminished effect or no effect in part because of this effect or dopaminergic circuitry. So it can be very challenging to find a signal.
The other one is what sometimes referred to as pseudo-specificity. So if you have improvement in a delusion, say someone is paranoid or if they have overwhelming hallucinations, they find it difficult to pay attention to other people or other activities, if you treat them successfully with an antipsychotic, their negative symptom ratings, avolition, anhedonia, blinded affect and so on may go down on rating scales. But this is kind of misleading. This is not a true improvement in the primary negative symptoms that are actually just a result of the illness directly.
So it's -- so we're talking about primary versus secondary negative symptoms. So primary negative symptoms in a sense, it's easier to understand if I explain what the secondary are. They are due to things other than the illness itself. So for instance, as I mentioned, positive symptoms can cause these negative symptom rating scales to go up, depression, anxiety, side effects of antipsychotics, substance abuse and then simply being socially isolated, which happens to many people with schizophrenia. So primary negative symptoms are not caused by these other factors other than a neurological, biological problem that is part of schizophrenia for many people with schizophrenia. So it's primary. It is not caused by secondary of these other things.
And so far, clinical trials haven't really had the right design, the right population. So recently, Cobenfy, the new muscarinic antipsychotic has been approved. They -- the company said that they had improvement across a range of symptoms, including negative symptoms. And on the rating scales, yes, negative symptoms went down. But the FDA said, wait a minute, they said the pivotal trials of Cobenfy supporting the schizophrenia indication for Cobenfy were not designed to capture changes in positive or negative symptoms as distinct groups.
In other words, negative symptoms that change whether or not there was a change in psychosis. Additionally, the pivotal trials for Cobenfy were not designed to evaluate the efficacy of drug in negative symptoms because the patients in the studies were experiencing exacerbations of schizophrenia, which can compound the assessment of improvement of negative symptoms when the positive symptoms improve. So how would you go about evaluating negative symptoms in a way that would let you gain an indication for the treatment of negative symptoms?
You need them not to have a change in positive symptoms. So you want people who enter the trial to have minimal and preferably stable positive psychotic symptoms, hallucinations, delusions, disorganization; and the same for dysphoria, anxiety and depression. So you don't want to use dopaminergic antipsychotics either because the signal can be obscured by the noise or -- of sedation, avolition and movement problems, motor problems.
And you also are -- may directly impact the structures in the brain that regulate emotion and also tend to regulate negative symptoms. And then it becomes impossible to distinguish why are these improving. Is it because you've improved these other things or because you've actually got something to what's intrinsic to the disease. And so you can kind of see the advantage of monotherapy trial design. It's the best way to isolate the drug effect on primary negative symptoms if you include patients who have positive and minimal -- I'm sorry, stable and minimal positive symptoms and anxiety/depression symptoms.
And the other thing of that is it's really to gain an indication, it's important to show an impact on function. Regulators, payers and patients care a great deal about function and quality of life. And one of the difficulties, of course, is an improvement in function is a lagging indicator. It takes a while, even if you have an effect -- a good effect for that to show up in rating scales because you have to remember many times these patients have lived for years with these negative symptoms. So they are tending -- going to tend to have smaller social networks, fewer opportunities for socialization, difficulties with social skills, decreased opportunities of a number of other kinds for recreation, for employment, and they're often going to have negative beliefs about their abilities. They're going to have poor confidence.
Now the way -- there are 2 or 3 scales that are accepted, the most influential for measuring this within schizophrenia is a scale called the Personal and Social Performance scale, the PSP. I'll be referring to that in the next few slides. So clinicians rate this scale. It's why they accept it as a measure of function in schizophrenia. It has 4 subscales, socially useful activities, work and study, personal and social relationships, self-care, which can often be [indiscernible] and disturbing or aggressive behaviors.
So here, we see the -- using that kind of design, monotherapy, stable and minimal positive symptoms and anxiety and depression in the Phase IIb study by Minerva of Roluperidone, you see, okay, the blue is placebo. And over here on the vertical axis, they all start out at 0 because this is change decline in the negative symptom factor scale. So blue, you can see some placebo effect. And in green, you have the 32-milligram dose, and it was significantly different and became significantly different, began to separate by the second week. The effect was bigger with the 64-milligram dose and it stayed and it was constant. And you see that the effect size for the 32 was pretty good. That's a little more than a usual definition of a medium effect size. And for the 64-milligram dose, it's close to what is called a large effect size.
Moreover, and this is particularly in -- it's encouraging because this is what matters for people when they're in their lives. You saw a significant improvement at the 64-milligram dose. The 32-milligram dose did not separate. And we'll come -- that has implications for future studies. And here, we go to the Phase III study. And what you can see is because it didn't really improve the PSP, it didn't have an impact on function. The study was solely of the 64-milligram dose, and it did meet the primary endpoint. And here, you see it separates, not quite significantly at 2 dose -- at 2 weeks, but then it stays significantly different throughout the study. Well, how about the PSP? You also see an impact on function in their lives. So going up is good. A higher score is good. And you see their separation at 4 weeks. And then at 8 and 12, it stays significant.
Now let me -- I'm sorry, before I get into that, the effect sizes of the PSP are not real large. But again, you need to keep in mind a couple of things. We talked about why it was a lagging indicator. You would expect it to continue to improve as they gained confidence and begin to have more success. But another thing that I think is really important is the effect -- even a relatively small effect size may make them able to benefit from psychosocial treatments. And the psychosocial treatments of schizophrenia are actually pretty powerful, [ stand ] once -- especially once psychotic symptoms are relatively well controlled. So this relatively small size may have big implications for their quality of life, their level of function because they're now more able to participate in psychosocial rehabilitation.
Now the FDA understandably had lots of concerns and questions at the beginning about a monotherapy. And they thought, well, these people are going to be relapsing a lot. But what you see here is something that's very interesting. This is what we call a survival curve. So it's really time to all causes discontinuation rates. So it's for lack of efficacy, it's for side effects for they're simply deciding they don't want to participate anymore. And everybody -- it starts at 1.0. So this is 100% of patients have not discontinued at the beginning of the study. And the lower it goes, the more have left the study for one reason or another. And what you see, the red line is these are the patients who took roluperidone in the 2 studies.
And the blue line, the comparison is really very interesting. They're large studies, one performed in the United States, the CATIE study with something like 1,400 patients. And the EULAST study, which was a European study. And what's very interesting about that is that unlike the patients in the roluperidone study, the patients in these 2 studies got -- in both of these studies got antipsychotic treatment. And yet you see the roluperidone group has a lower relapse rate over this -- over a number of months. So the FDA is now reassured about that. They say, well, maybe it's partly because of the nature of this population you're studying, which is maybe a contributor. And maybe it's just that there's something about roluperidone that has an effect perhaps directly on psychotic symptoms, perhaps indirectly, maybe through emotion, they are not discontinuing. They're not stopping. They're not being taken out of the study or leaving it on their own.
So what are the overall conclusions from this? Roluperidone demonstrated clear statistical significant on multiple efficacy endpoints, proves what we consider primary negative symptoms that improves functioning, improves avolition, no change in positive symptoms or anxiety/depression. They started out minimal and stable and they stayed that way. And monotherapy was associated with a low relapse rate and low discontinuation overall. There was no evidence of the well-known disabling side effects that are often observed with antipsychotic treatment. Changes in metabolic measures, so increased risk of diabetes, for instance, sedation, motor symptoms, which are common in those drugs, elevation of prolactin hormone that can have some bad effects if high for over a long period of time.
And unlike the muscarinic drug, no nausea. And there's -- this is exciting. It's a novel pharmacological profile, derives differential clinical benefit in both of these studies. And as a physician who sees patients a lot, having another mechanism of action is really important for patients. It's one of the reasons hypertension and diabetes have much more success if patients take their medications because they have multiple mechanistic classes. And so someone who doesn't benefit or can't tolerate a drug in one class may do much better in another class. And since my entire career, we've had, in a sense, one mechanistic class. We now have 2. This becomes a third, which is pretty exciting.
And I'll turn the conversation over now to Dr. Remy Luthringer.
Thank you so much, Greg and Brian. I'm sure that you will get a lot of questions because you addressed a lot of important points. So let me focus in the last few minutes about -- on the proposed Phase III confirmatory trial we have exchanged a lot with the FDA. So here, you have the study design. So sorry about this complicated slide. But so basically, you could cut into 3 pieces of the study. The first part, which is on the complete left is the screening period. And the screening period is for 1 month in this study.
But what is very important during the screening period is to really make sure that you get access to the right patients such that you are screening the right patients for the study. When I speak about right patients, this is where we got really consensus and discussion, which came to a conclusion that, yes, indeed, I mean, we should include like in the 2 previous studies, patients who have stable positive symptoms and stable negative symptoms over a period of time of 6 months and have a certain level of negative symptoms, which are impairing. So it's based really on very simple criteria, but I mean, this is allowing to really select the right patient population.
Afterwards, you have really the key part, which is in green here or which is called Part A. And this is really looking to efficacy as to reconfirm the efficacy we have seen in the 2 previous studies. You see that, I mean, we will measure efficacy at week 12 like in the 2 previous studies. And here, the study design is roluperidone 64 milligram. So the only dose we're testing here is 64 milligram, which was the highest dose we have tested in the 2 previous studies versus placebo. So this is obviously double-blind part. So this is really to reconfirm or to show that, I mean, the roluperidone is improving negative symptoms and because we have as a sole key secondary endpoint, PSP to confirm that this is, how to say, transforming or negative symptoms improvement is having an impact on functioning.
When the patients have completed this part, again, which is very similar to what we have done in the 2 previous studies, part of only having one dose versus placebo, patients go into Part B or the third part of the study. And this part is mostly focused on looking to relapses of positive symptoms. So as Brian said, clearly, I mean, we have seen in the 2 previous studies when we were using open-label extension, we have seen a very low relapse rate of positive symptoms in this patient population we are including in our trial.
And here, what we are doing or what the FDA is asking us to do, and I think it is very important is not only -- not to control animal versus placebo or to have an open-label extension, but to compare 64 milligram of roluperidone versus standard of care, so basically versus antipsychotics.
So the study design we are using here in order to really maintain the blinding as much as possible is what we call a double-whammy approach. So basically, each patient will get a tablet of roluperidone active drug or placebo and the capsule of active antipsychotic or placebo of the antipsychotic. So we are testing here or we are including 3 antipsychotics to compare to roluperidone. And you see that the patients from Part A are rerandomized equally to 64 milligram of roluperidone or placebo. So this is how the study will be conducted moving forward.
Now going more into the details. So again, as I said, the very important part here is Part A, the 12-week double-blind placebo-controlled study versus roluperidone. You see that it is a study with 380 patients. And what is important here is that the primary endpoint is exactly the same as the one we have used in the previous study, in the Phase III study. And we have elevated like in the Phase III study, the sole key secondary endpoint is -- functioning is PSP. And so very, very, very similar to what we have done in the past. And because it is 64 milligram, remember, 64 milligram showed a significant effect compared to placebo. The statistical analysis is a classical MMRM analysis, which is what most of the companies are using and what the FDA likes to see as an analysis.
Going now to the second part of the Part B. So again, this is really focusing on safety/number of relapses in this patient population when you're comparing roluperidone to standard of care. And so here, in terms of analysis, because we have such a limited number of relapses, you can only do a qualitative analysis of the relapses. You cannot do statistics here, and this is something we have discussed as well. And so this is, again, looking to using our drug in monotherapy, what is a long-term safety/relapse rate when you treat them with roluperidone compared to having patients treated with antipsychotics.
So this is a very important part as well because if we are reconfirming the results we had in the 2 previous studies, which were open-label extension, low relapse rate, this shows that, yes, this population exists and this population can be treated in monotherapy and the risk of relapses of positive symptoms is really minimal.
Now, obviously -- and this is a very important slide, and this is summarizing all the attention of the team on executing the trial, this confirmatory trial. First of all, I will not insist too much on the number of patients and the number of sites. But here, we are really trying to limit the number of sites to 40 sites because it's well described that having too many clinical sites has an influence on the variability of the data and you might lose the signal even if the signal is very present. So we really are focusing on 40 sites. You see that we will have patients coming from the U.S. and from 4 European countries.
Now the second aspect, which is very, very important, and we have started with this even before we were sure that we get the financing, we have started to work again on site selection and really based on quality performance metrics because sometimes one site can be extremely good 2 years ago and for a reason or another, is no longer performing extremely well. So we really have used a lot of criteria here to come up with the right set of clinical sites.
First of all, I mean, some of the sites have participated to the Minerva trials -- the previous Minerva trials. And we have data, we can analyze and we can reconfirm to see if the site is doing exactly the same quality work as before. But we have also access to other information and you will see that the CRO in the next slide, the CRO we have selected has a lot of expertise or a lot of experience and recent experience of running trials in schizophrenia. And clearly, their input, their knowledge about the quality of the clinical sites who will be part of these 40 sites was also extremely important in selecting the sites.
And last but not least, our provider who will do the online monitoring of the quality of scoring has also a lot of experience. So we really put all this experience together in order to come up with the right sites, with the appropriate staff or people running the study, people who are used to do the rating of the PANSS scale. And they need also to have the appropriate number of patients, yes, because if you have one site only recruiting a patient from time to time, each 3 months, the learning curve is no longer there, and they start from the beginning, and this might induce some variability. So one criteria was also sites who have really the potential to recruit patients.
Now the last bullet point here is key. Because what we have to do here is try to apply all what Brian explained and all what you have learned from the previous studies to minimize the potential placebo effect, but to maintain also the roluperidone improvement we have seen in the 2 previous studies. Keep in mind that when you're looking to the 2 previous studies, the improvement seen on negative symptoms with 64 milligram is very similar between the 2 studies. So the drug is always performing in the same way.
So, what can we do in order to keep this discrimination between the placebo effect and the roluperidone effect? So the first thing, and I think Brian addressed this briefly, and this is very close to my heart because I started as a psychiatric nurse is a nursing effect. When you spend time with the patient, keep in mind that these patients, when they have negative symptoms, and Brian said this very clearly, the social interactions are becoming limited -- very, very limited. Suddenly, they are in a trial, they see study nurse, they see a clinician, they see the rater and they get attention. So this might have an effect indeed, which is not sustained over time, but has an effect on improving negative symptoms. So this is what I call the nursing effect. So what we have decided in this study is to reduce interactions with the patient. And compared to the previous Phase III, the interaction is really reduced to when the patient has to be scored with the clinical scale. So this is one aspect, which is very important.
The other aspect is intensive training of the raters for the PANSS scale, and I could also put here the PSP scale. Keep in mind that, I mean, most of the trials are done for antipsychotics, where patients have an acute episode of positive symptoms. And so this is quite easy to score, whereas scoring negative symptoms using the PANSS scale is a little bit more challenging. So here really, we also are focusing a lot of our efforts to really help the raters to understand how to use the part for negative symptoms from the PANSS scale.
The other aspect, which is not really related to the execution of the trial, but which is important is that it is very well described in the literature that if the expectation to get active drug is high, you have a tendency to have an inflation of placebo effect. And keep in mind that in the 2 previous studies, we had 2 doses of roluperidone versus placebo. So 2/3 of the patients were receiving active drug versus 1/3 placebo. So the expectation was higher than in this trial where the randomization between active drug and placebo is 1:1. So this is a very important aspect, not specific to our trial, which is well described in the literature, but which is important.
The other aspect is, again, coming to the selection of the patient, getting the right patients into the study is very, very important to reduce the noise. And this is a difference compared to what we have done in the previous trial. In the previous trial, it was purely the decision from the PI. It's still the decision from the PI in this trial, but what we are doing here, and this is more to help the PI to take the right decision. We will have a small committee discussing each patient's inclusion to the study. It's just to say, are you sure about this aspect? So just to enhance the quality of the patients going into the study.
The next bullet point is key here, is to use this service provider who has a lot of experience in order to monitor the blinded data when they are generated online to monitor the data. And here, we are going down not only to the level of the clinical sites, but we are going down to the level of the person who is doing the scoring. So we will have such kind of monitoring of the rating or the quality of rating from each scorer at each site. And this is very important. But what we have added here and we have really the chance to have someone who has joined our team who is one of the world-leading experts in overseeing clinical trials. And so in combination between the service provider and the person who have joined our group or our company, we have really very strong tools to really assess online if someone is deviating from the standard deviations of scoring, which is allowed in this -- with the scale we are using here in PANSS and the PSP.
We have also -- we are using also e-tablets here, which are very important because they are prompting the person who is doing the scoring about discrepancies. I'll give you an example. If you score worsening of negative symptoms and you score improvement of PSP or CGI-S, this is not completely accurate. So the tablet is not correcting what the scorer is doing, but it's just asking the question, are you sure about what you have done here? So all in all, this gives more help to the scorer to do the right thing.
And last but not least, because we have only 1 dose versus placebo, we do not care about the type 1 error correction we had in the previous Phase III trial where we had to use the Hochberg correction and to claim that you have a positive study, you need to have the 2 doses showing a p-value in the previous Phase III, it was only the highest dose. In this case, we're only testing the highest dose. So no concern about the type 1 error correction. So I think when having all these things in motion in order to come up with the highest quality of execution of the trial, I think the probability of success is really enhanced.
Now this is the update on where we are with the study. We have appointed Syneos as a CRO. And I was saying in my previous slide that Syneos has a lot of experience in running trials in schizophrenia. They have been involved or they have run with the help of, obviously, the sponsor. They have run the Karuna study, the studies of the first drug with a new mechanism of action. So this is very recent experience Syneos has in running clinical trials in schizophrenia. So really, we are really happy that Syneos is our partner to run this study.
We have already activated multiple sites. And as I told you before, this is a long process. I mean, we have worked on this over the last few months, quasi 1 year in order to come up with the right sites to participate to this trial.
We will have first patient in Q2 2026. All is moving according to plan for this. And afterwards, based on the feedback from Syneos, based on the feedback from our previous experience and from different sources, we estimate that -- I mean, we will have the top line results of the primary efficacy endpoint, so the week 12 efficacy endpoint. We will have this in the second half of 2027 and the results of the relapse part in the second half of 2028.
And so what we are doing, and this is ongoing, I mean, we continue our dialogue. We keep the agency, the FDA informed about progress. And when we have the top line results of the 12-week primary endpoint, we will obviously share this with them and discuss about what is the best way moving forward in terms of resubmission of our NDA.
So this is just to say, again, we are so proud that, I mean, we have all these top-tier investors who have really done a lot of due diligence on our data and came to the conclusion that it is worthwhile to finance us.
So before handing over for Q&A, let me just summarize again, the Minerva Conference. I think here, we are in an exceptional good situation and unique situation. First of all, we have the pharmacological tool. We have the drug, which is really what you need. And we have already clinical data. The truth is in clinical data. We have 2 studies where we could really demonstrate that the drug has an effect and has an effect also on primary negative symptoms, which is extremely important.
I think with all the very important and constructive exchanges we have with the FDA, and this is still ongoing. I think we are coming up with the right Phase III trial design to confirm that, I mean, roluperidone is really the right molecule for patients with negative symptoms.
And again, I think it is really the right moment, as I was mentioning in one of my previous slides because here, we have really the alignment of the regulator who is really open to -- for a paradigm shift and to approach the treatment or the assessment of negative symptoms of roluperidone in the way I was just describing. I think the medical and scientific community is making a lot of progress and is ready to such kind of paradigm shift. And indeed, I mean, having the top-tier investors who really help us to go to the finish line with roluperidone is obviously important.
So this is what I wanted to tell you. And I think I hand over to Corey for Q&A.
We'll have Tara handle the next segment of the Q&A, and then I'll do the written section. But go ahead, Tara.
[Operator Instructions] Our first question comes from Andrew Tsai at Jefferies.
2. Question Answer
It's very informative and congratulations on the progress. So first question is just around powering assumptions for the 12-week portion. How did you power the study? What kind of placebo-adjusted Marder score change would you like to see? What did you assume for placebo, for instance? And then same for the 40-week portion as well. I'm assuming the end goal is to show no significant increase in relapse versus an antipsychotic. But is there some leeway here? And can you maybe talk about what the qualitative bar for success would be?
I think this is for me. So thank you, Andrew, for your question. So the first 12 week is powered 90%, yes. So it's powered 90% we have estimated a difference between placebo and treatment of 1.8 -- 1.5, 1.8. And these are the assumptions. We have also taken the same relapse rates we had in the previous trials that's -- sorry, not the same dropout rates, excuse me, of the previous trial because these are the 3 criteria used in order to power the study. So this is what we have done.
What I can tell you because this was important discussion also not only with the regulator, but with our investors, the study is overpowered, basically, this is more than 90% powered because the powering assumptions I was telling you was with around 300 patients. So we decided to go with 380 patients to have the room left to have enough patients to go to the week 12.
Now concerning the second part, as I said in my presentation, we had really very limited relapses in the 2 previous studies. Also, as I said, it was an open-label extension. If you remember, in the Phase III study, we had less than 15% of relapses over a period of 1 year. When you're looking to the meta-analysis, which have been done on antipsychotics, the relapse rate is about 20% to 35%. So clearly, because of our patient population, and I am also very convinced that our drug has an effect on keeping these patients stable in terms of positive symptoms.
Think one second about the 5-HT2A activity, I mean, which has been demonstrated in the past by several people to be protecting against worsening positive symptoms. I think, this explains why we have this low level.
Now what the FDA wants to suggest is head-to-head, I mean, in the same study with the same patients, what -- how it looks like. We already have data, as you have seen the data presented by Brian, yes, we have analyzed the CATIE and EULAST database. We have extracted the patients who have the same eligibility criteria as our patients and the relapse rate is very similar between the 2 patients treated with antipsychotics versus patients treated with roluperidone. So long story short, just to give the context that people understand what we are doing here, I think what the FDA is looking for is something which is very similar between the 2 groups.
There is some room left. Obviously, if one group, say, goes to 50% of relapses and the other one is at 10%, this is a problem. But I mean, if we are in the ballpark with some variability, I think this is what you need. And again, because we have such a low relapse rate, you cannot do some formal statistics. You cannot do, for example, an inferiority study. It's just impossible because we have not enough cases. This would be a 2,000-patient study. So clearly, it is purely descriptive.
Can I -- just one quick follow-up then. I'll be mindful of acquaintances. Can you file after the 12-week data as the 40-week data is being produced? Is that basically a rolling kind of NDA possible, for instance? Or do you truly have to wait for every patient to complete all 52 weeks before filing?
It's a great question. And so, I can obviously not decide for the FDA. I mean the FDA has to decide. But what I can tell you is that we have really this very constructive dialogue going on with the FDA. We have planned to share immediately the 12-week data, primary efficacy endpoint with the FDA. And we will see what is the best way to resubmit our NDA. This is just my personal opinion, but this is such an unmet medical need. If I think the 12-week data are showing that, I mean, we have a good discrimination between placebo and treatment that we have a p-value and that PSP is also improving, I hardly see that we have no room left in order to negotiate things with the agency.
Keep also in mind that we will already have also some data about the relapses. We will not have all the patients, but we will already know blinded how many patients are relapsing, yes. So I think we will have a lot of data in hand.
And last but not least, I think it's also important for people to understand. This is a resubmission of our NDA. And so the review time is 6 months and not 10 months or 1 year. So this is a 6-month review time.
Our next question comes from Douglas Tsao at H.C. Wainwright.
Congrats on the progress. I guess a question to Dr. Strauss and Dr. Kirkpatrick. I can understand the need to sort of have a monotherapy study to sort of really isolate the effect of roluperidone, right, versus what may be sort of a compounding factor introduced by antipsychotics. When we think about the sort of natural history of those patients, and I think Dr. Strauss, you sort of showed a curve showing the relationship between the positive and negative symptoms. How do you anticipate the sort of the timing or the best time or sort of the relevance of roluperidone in terms of an intervention?
I can see in the early stages before you have the significant number of psychotic events or later, right, when the positive symptoms sort of really sort of seem to go into a quiescence period that roluperidone would be -- and negative symptoms persist that roluperidone would be perfect. But what about this time period when we still see a lot of sort of psychotic breaks or psychotic episodes. I know, there is evidence that roluperidone shows improvement in terms of relapses, but how should we think about the potential use of roluperidone as a monotherapy in that population?
Remy, how many -- what was the proportion of people in your studies who were, for instance, below the age of, say, 35.
Below 35?
Yes. What would you guess?
It was around -- don't blame me if it is not completely correct, but I think it was around 15% to 20%.
Okay. So there's -- I don't think there's reason to believe it would not be effective for the same -- if you use the same criteria for picking them, I think in patients with psychosis, age ma -- has made some difference with regard to side effects in children, but we're not proposing for children. And I think young people will respond to antipsychotics well. There's no -- I don't think there's a strong reason to believe that it has to be restricted to people who are 35 or above.
So the other thing is I would not be surprised, American psychiatrists tend to like to do things separate from guidelines. I would not really be surprised if they ended up combining saying, well, this person doesn't really have motor side effects or anhedonia because they're antipsychotic. So I'm going to add it on to an antipsychotic.
If I can add to that. I would even say we know that as the illness becomes more chronic, the environmental influences on negative symptoms do strengthen. So the fact that roluperidone has shown an effect in these highly chronic patients is really reassuring. It should be less likely to show an effect on people whose environments have become entrenched and are less likely to promote change.
And I would think that people earlier in the illness, first episode, early course, even the prodromal phase, who've maintained their social networks, who have more support. The environment has not become as degraded. They may have more plasticity, if you will, to show these effects.
If you allow me, Doug, to add something here is -- [ all is ] about how you label the drug. And again, for the moment, obviously, we have not a final conclusion about the labeling. But -- so what we are proposing here and what we are doing basically in the trial, I mean, is the following: we take patients who are stable over the last 6 months, afterwards the clinician will decide what the stability is. But I mean, we take patients who are stable. And here, the clinician can take the decision if he wants to treat or to stop the antipsychotic and to treat with roluperidone.
And so what we are suggesting, what we are proposing because people should not understand that we are against antipsychotics. I think antipsychotics are useful, but as major tranquilizers for the reason for why they have been developed. So what we are proposing here is that, I mean, if we have a relapse, again, it is limited with roluperidone. But if we have a relapse, you stop roluperidone and you treat the relapse with an antipsychotic. And afterwards, when the patient is stable again, indeed, I mean, you can think again about putting roluperidone in monotherapy.
And I like something which has been published by someone who is important at the FDA, which is to say, look, positive symptoms is like having fever in an infection, where the infections are negative symptoms. So I think it's a quite nice picture of how you could think about using roluperidone in the case of clinical practices.
We'll go to some written questions now being mindful of time. I want to try to wrap this up in 6 minutes or so. We got some great written questions here. Hopefully, we can get through all these.
The first one is, many symptoms of psychiatric diseases occur in multiple diagnoses. And is that true also with the negative symptoms of schizophrenia that you described here? In other words, if it works in schizophrenia for these negative symptoms, what are the other indications that might be possible to take roluperidone into?
I can start that one off. So we know -- I would say the markets for this would be psychotic disorders other than schizophrenia. So there are other psychotic disorders like schizophreniform, schizoaffective that display negative symptoms. The prevalence rate for schizophrenia is 1%. The prevalence rate for all psychotic disorders is about 3%. So that's number one.
Number two would be the prodromal phase of illness. So in the DSM, there's a condition called the attenuated psychosis syndrome. And this is people with this pre-illness presentation who have attenuated positive symptoms but often have negative symptoms that are fully fledged.
And the third would be neurological disorders. We know that a range of neurological disorders do have clinically significant negative symptoms. So for example, Alzheimer's, Parkinson's, traumatic brain injury would be some common ones. So I think we know that the mechanisms underlying negative symptoms are cross-cutting cortico-striatal circuitry are going to be involved across diagnostic boundaries. And so I think all of these would be relevant targets.
Great. Next question gets to avolition. So maybe speaking -- sticking to you, Greg, is that you're showing avolition as the centerpiece of capturing that effect on negative symptoms. But can you elaborate a little bit more on how the primary endpoint that's being used in Phase III is configured to be able to ensure that you do capture that effect on avolition that roluperidone has shown in the previous studies.
Yes. That's a good question. So the primary endpoint, the PANSS negative symptom scale has a range of items related to negative symptoms, including multiple that tap into avolition and some that tap into the other domains, asociality, blunted affect, et cetera. And so it definitely enables the proper type of mathematical approach to be applied like we did before using network analysis to see if that centrality effect replicates from a network perspective. And there would be no reason to think that it wouldn't since it replicated once already from the Phase II to the Phase III trial.
And it raises an interesting possibility that really the strongest effect would be a drug that is relatively specific for avolition and that could change what kind of animal models you use and what kind of preclinical human models you used for drug discovery.
The next question on mechanism of action and asking you to start, Dr. Kirkpatrick is, can you elaborate more on just your view on this mechanism of action as the mechanism itself as important now that we have clinical data, but just speak to that in relation to the other classes of drugs that act in dopamine and the muscarinic receptors.
Yes. It's -- I mean there are a number of things to be said. I'll try to be brief. But, the 5-HT2A, the serotonergic effect is really very interesting because there's another literature that's been -- didn't lead to drug development, particularly, but that drugs for that receptor are actually antipsychotics, which is very interesting. And that's one of the -- certainly one of the important mechanisms that's going on with roluperidone, and we have a hint that it might act as an antipsychotic. But I was talking more generally about the clinical efficacy of having multiple mechanistic classes.
And that's very helpful for patients with a wide variety of diseases because efficacy is going to vary from person to person to some extent in other disorders, it -- the efficacy is better for one mechanism than for other for the individual. And also side effects are a big issue, especially metabolic side effects these days. So having medications that have -- even if they have the same overall prevalence of significant side effects, having different ones, really, that's a real advantage for patients because patients -- one patient may be sensitive to A but not B and another patient, the exact opposite. So it's interesting theoretically in terms of pharmacology and also just practical use for patients to have a new mechanism of action.
Great. All right. Last question, and then we'll wrap it up. And after this question, we'll turn it back to Remy for some closing remarks, but this comes from Tom Shrader at BTIG, who's asking about the placebo rate in the upcoming Phase III. You spent a lot of time elaborating on things you're going to do to minimize the placebo effect. But he asked, do you agree that a key to being able to separate active from placebo is how fast the placebo patients decline? Do you agree to that? And then the second part of it is, is that a rate that you expect in the placebo arm consistent in other trials in schizophrenia?
So I'm not completely sure that I understand the first part. So decline, you mean improve, I guess. So this is -- because they do not decline, they improve on the placebo. They are just not improving as much as with treatment. And in addition, the effect is not really maintained over time. So -- but clearly, all what I described here, I think, will definitely help to bring the placebo effect to a level which is probably closer to the Phase IIb than to the Phase III trials, because keep in mind one second that here, we have a drug and Brian just said it without side effects like what we have with antipsychotics. You have a very, very successful Phase IIb study, and you propose this trial to patients.
So clearly, and also having 2 doses, the likelihood to get active treatment. All this is described in the literature to make the placebo effect bigger. So all this is no longer present in this new trial or in this confirmatory trial. So I think really, we will really be able to control much better the improvement of placebo.
Now concerning the second question about comparison with other trials, I think the short answer is you cannot compare our trial with all the trials which have been done because, first of all, if you compare to trials which are looking to acutely relapse patients for positive symptoms, Brian, I think, explained this very well. And the FDA even pointed it, this is a pseudo improvement that you just bring maybe your patients back to baseline of the course of the disease in terms of negative symptoms.
So the only company who has done something very similar in terms of study design like we have done is Lundbeck, and they have even published the data, which I think phosphodiesterase 10 (sic) [ PDE10A ] inhibitor. But unfortunately, the drug did not work. So they used exactly the same study design. So long story short, today, we have no comparison.
All right. Fantastic. I think we'll wrap it up there on behalf of LifeSci, I just wanted to thank Greg and Brian for all their insightful comments today. And thank you all for listening. And I'll turn it back to Remy for some closing remarks.
So I can only echo what you're saying. I mean, Brian and Greg really thank you for being here today and also having already published on our data and continue to help us doing the right things and analyzing hopefully the right -- in the right way, the next studies and thinking about how large and how -- what is next after this trial because as you very well said, I mean, this is a transdiagnostic problem is negative symptoms. It's not specific to schizophrenia. So thank you again for being here. I would like also to thank once more our investors. Believe me, they have done a lot of due diligence, and they help me even to analyze the data through different angles. And always, I mean, you see that you have a drug effect. So thank you to all what they have done and their support.
And I'm really looking forward to this continuous dialogue with the FDA. And one aspect I would like to highlight, and I have the chance to interact quite often with patients or with patients associations. And I'm really thinking about patients. Patients really deserve a treatment for negative symptoms. As you heard, this is what is impairing their life and making their life difficult. So this is what is driving Minerva and all the people who are helping us to bring roluperidone to the finish line. So thank you for your time, and we will keep you updated about the progress as you have heard. We are close to start recruitment. So stay tuned. Thank you for your time.
Transkripte auf Deutsch freischalten
- Alle Event Transkripte auf Deutsch
- Sofortige Übersetzung
- KI-Zusammenfassungen für die wichtigsten Insights
Minerva Neurosciences Inc — Special Call - Minerva Neurosciences, Inc.
Finanzdaten von Minerva Neurosciences Inc
Umsatz
Der Umsatz stellt die Summe aller Einnahmen eines Unternehmens z. B. für dessen Produkte oder Dienstleistungen dar.
Umsatz (TTM) einfach erklärtDirekte Kosten
Direkte Kosten sind die Kosten, die direkt im Zusammenhang mit der Herstellung des Produkts oder der Dienstleistung entstehen.
Bruttoertrag
Der Bruttoertrag gibt an, wie viel vom Umsatz nach Abzug der direkten Herstellkosten im Unternehmen verbleibt. Berechnet man den prozentualen Anteil vom Umsatz, spricht man von der Bruttomarge (engl. Gross Margin).
Brutto Marge einfach erklärtVertriebs- und Verwaltungskosten
Die Vertriebs- & Verwaltungskosten (engl. Selling, General & Administrative expenses, kurz SG&A) beinhalten alle Aufwände für Marketing und den Verkauf sowie die allgemeine Verwaltung des Unternehmens.
Forschungs- und Entwicklungskosten
Die Forschungs- und Entwicklungskosten (engl. research & development costs, kurz R&D) geben Auskunft darüber, wie viel das Unternehmen in die Forschung und die Entwicklung seiner Produkte investiert. Vor allem prozentual vom Umsatz und im Vergleich zu direkten Wettbewerbern sind die Kosten interessant.
EBITDA
Das EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) ist der Gewinn des Unternehmens vor Zinsen, Steuern und Abschreibungen. Berechnet man den prozentualen Anteil vom Umsatz, spricht man von der EBITDA-Marge.
Abschreibungen
Abschreibungen stellen Wertminderungen von Vermögensgegenständen des Unternehmens dar (z.B. durch Abnutzung von Maschinen).
EBIT (Operatives Ergebnis)
Das EBIT (engl. Earnings Before Interest and Taxes) ist der Gewinn des Unternehmens vor Zinsen und Steuern, das auch als operatives Ergebnis bezeichnet wird. Berechnet man den prozentualen Anteil vom Umsatz, spricht man von
der EBIT-Marge.
Nettogewinn
Der Nettogewinn stellt den Gewinn oder Verlust nach Abzug aller Kosten dar.
Nettogewinn einfach erklärtaktien.guide Premium
| Jun '26 |
+/-
%
|
||
| Umsatz | - - |
-
100 %
|
|
| - Direkte Kosten | - - |
-
-
|
|
| Bruttoertrag | - - |
-
-
|
|
| - Vertriebs- und Verwaltungskosten | 20 20 |
104 %
104 %
-
|
|
| - Forschungs- und Entwicklungskosten | 16 16 |
138 %
138 %
-
|
|
| EBITDA | - - |
-
-
|
|
| - Abschreibungen | - - |
-
-
|
|
| EBIT (Operatives Ergebnis) EBIT | -35 -35 |
117 %
117 %
-
|
|
| Nettogewinn | -395 -395 |
3.619 %
3.619 %
-
|
|
Angaben in Millionen USD.
Nichts mehr verpassen! Wir senden Dir alle News zur Minerva Neurosciences Inc-Aktie direkt und kostenlos in Deine Mailbox.
Auf Wunsch erhältst Du jeden Morgen pünktlich zum Frühstück eine E-Mail, die alle für Dich relevanten Aktien-News enthält.
Minerva Neurosciences Inc Aktie News
Firmenprofil
Minerva Neurosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entwicklung und Vermarktung eines Portfolios von Produktkandidaten zur Behandlung von Erkrankungen des zentralen Nervensystems befasst. Seine Produktpipeline umfasst Roluperidon, Seltorexant, MIN-117 und MIN-301. Das Unternehmen wurde am 23. April 2007 von Rogerio Vivaldi Coelho gegründet und hat seinen Hauptsitz in Cambridge, MA.
aktien.guide Premium
| Hauptsitz | USA |
| CEO | Dr. Luthringer |
| Mitarbeiter | 7 |
| Gegründet | 2007 |
| Webseite | www.minervaneurosciences.com |


